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human	 body.	 The	 use	 of	 neuromuscular	 blocking	 agents	 to	 inhibit	 neuromuscular	
transmission	 is	 sufficient	 to	 produce	 skeletal	 muscle	 paralysis,	 a	 mechanism	 used	 to	
facilitate	muscle	 relaxation	 during	 surgery.	 Residual	 neuromuscular	 block	 postoperatively	
has	 been	 found	 to	 be	 a	 major	 risk	 factor	 for	 postoperative	 complications.	 Sudden	
reinstatement	of	neuromuscular	block	(recurarisation),	through	use	of	magnesium,	has	also	
been	observed	clinically.	This	has	led	to	a	reluctance	to	use	magnesium	postoperatively	for	
fear	 of	 recurarisation.	 Recurarisation	 following	 reversal	 of	 neuromuscular	 blockade	 with	
neostigmine	or	sugammadex	has	not	been	evaluated	in	a	formal	study,	and	for	this	reason,	
this	study	investigated	recurarisation	after	30	mg/kg	magnesium	sulphate	(MgSO4)	following	
reversal	 of	 neuromuscular	 blockade	 with	 neostigmine,	 two	 dosages	 of	 sugammadex	 or	
when	reversal	was	omitted.	Prior	to	investigating	recurarisation,	the	effects	of	magnesium	




with	 isoflurane	 and	 the	 common	 calcaneus	 tendon	 attached	 to	 a	 force	 transducer.	 	 The	
response	 of	 the	 muscle	 to	 train-of-four	 (TOF)	 supramaximal	 stimulation	 was	 recorded	
electronically	and	captured	to	a	spreadsheet.		Sciatic	nerve	stimulation	was	performed	as	a	
TOF	 stimulus	 every	 20	 sec	 throughout	 the	 experiment.	 During	 a	 5-minute	 stabilisation	
period	 baseline	 measurements	 were	 obtained.	 During	 recordings	 TOF-R	 and	 %T1	 values	
were	measured.		
During	the	magnesium	dose-effect	experiments,	each	rat	was	given	a	bolus	dose	of	one	of:	







of	 reversal	 of	 neuromuscular	 blockade	 were	 then	 adopted.	 The	 first	 group	 received	 no	




>	 0.9,	magnesium	 sulphate	 (30	mg/kg)	 was	 administered	 and	 the	 effect	 recorded	 for	 15	
minutes.	
In	the	magnesium	dose-effect	experiment:	No	neuromuscular	impairment	(TOF-R	and	%T1)	
was	 observed	 in	 the	 magnesium	 10	 and	 30	 mg/kg	 groups.	 	 In	 the	 60	 mg/kg	 group,	 a	
significant	reduction	(compared	to	saline)	of	TOF-R	(0.253)	of	relatively	brief	duration	was	
seen,	 but	 the	 depression	 of	 %T1	 (24.0%)	 was	 not	 statistically	 significant.	 	 At	 100	mg/kg,	
significant	impairment	of	both	%T1	(58.0%)	and	TOF-R	(0.498)	was	seen	that	lasted	beyond	
the	duration	of	the	recording.	
In	 the	 magnesium	 recurarisation	 experiment:	 recurarisation	 was	 observed	 in	 all	 reversal	
groups.	Recurarisation	was	maximal	following	SPON,	with	a	maximum	reduction	of	TOF-R	of	
0.451.	Recurarisation	after	SUG4	assessed	by	TOF-R	was	depressed	by	0.280	that	was	not	





Recurarisation	 was	 observed	 after	 magnesium	 was	 administered	 following	 all	 forms	 of	
reversal,	 but	 was	 greatest	 following	 spontaneous	 recovery	 or	 reversal	 with	 4	 mg/kg	 of	
sugammadex,	 however	 by	 increasing	 the	 dose	 of	 sugammadex	 (to	 16	 mg/kg)	 used	 for	
reversal	the	recurarisation	effect	was	minimised.		
In	conclusion,	the	continued	occurrence	of	magnesium	recurarisation	in	rats	reversed	with	
moderate	 doses	 of	 sugammadex	 is	 most	 likely	 explained	 by	 sufficient	 extraction	 of	
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Appendix	 Table	 5:	 Descriptive	 statistics	 of	 average	 isoflurane	 concentration	 in	 the	
magnesium	dose-effect	experiment.			
Appendix	 Table	 6:	 Descriptive	 statistics	 of	 average	 isoflurane	 concentration	 in	 the	
magnesium	dose-effect	experiment.			
Appendix	 Table	 7:	 Descriptive	 statistics	 of	 the	 time	 from	 induction	 of	 anaesthesia	 to	
administration	of	magnesium,	in	the	magnesium	dose-effect	experiment.			
Appendix	 Table	 8:	 Descriptive	 statistics	 of	 the	 time	 from	 induction	 of	 anaesthesia	 to	
administration	of	rocuronium,	in	the	magnesium	recurarisation	experiment.			
Appendix	 Table	 9:	 Descriptive	 statistics	 of	 the	 baseline	 TOF-R	 prior	 to	 administering	
magnesium,	in	the	magnesium	dose-effect	experiment.			











This	 thesis	 concerns	 magnesium’s	 ability	 to	 reinstate	 drug-induced	 paralysis	 (known	 as	
neuromuscular	 block)	 after	 apparently	 adequate	 recovery,	 through	 its	 action	 on	 the	
functional	 contact	 point	 of	 the	 nerve	 and	 muscle	 (neuromuscular	 junction).	 Intravenous	
magnesium	 sulphate	 has	 many	 therapeutic	 applications	 in	 the	 pre-,	 intra-	 and	 post-
operative	period.	Unfortunately,	due	its	ability	to	potentiate	neuromuscular	block	produced	
by	neuromuscular	blocking	drug	used	during	anaesthesia,	its	use	is	generally	avoided.	When	
magnesium	 interacts	 with	 these	 drugs,	 it	 tends	 to	 leave	 a	 degree	 of	 residual	 muscle	
weakness	 postoperatively,	 and	 thus	 its	 use	 in	 the	 perioperative	 period	 is	 often	 advised	
against.	This	is	due	to	residual	muscle	relaxation	after	general	anaesthesia	being	associated	
with	 respiratory	 complications,	 especially	 when	 an	 endotracheal	 tube	 is	 not	 supporting	
ventilation	or	protecting	the	airway	from	aspiration	of	vomitus.	
The	use	of	pharmacological	 (drug-based)	methods	to	reverse	neuromuscular	block	has	 for	
over	 50	 years	 involved	 enhancing	 the	 chemical	 signal	 from	 the	 nerve	 to	 the	muscle	 and	
overpowering	 the	 neuromuscular	 blocking	 drug,	 with	 a	 drug	 known	 as	 neostigmine.	 	 A	
recently	 developed	 pharmacological	 method	 of	 reversing	 neuromuscular	 block	 induced	




block	 (recurarisation)	 between	 the	 different	 pharmacological	 regimes	 of	 reversing	
neuromuscular	block	are	lacking	in	the	literature	and	magnesium	has	such	potential	for	use	









The	neuromuscular	 junction	 (NMJ)	 is	point	of	 contact	of	 the	nervous	 system	to	a	 skeletal	
muscle	fibre.	Here,	chemical	transmission	of	the	neural	signal	across	a	synapse	is	necessary	




nerve	terminal	containing	the	ACh-filled	synaptic	vesicles	 ( )	 located	at	 the	active	zones	
adjacent	to	voltage-gated	calcium	channels	( ).	The	neuromuscular	cleft	is	made	up	of	a	















approaches	 the	muscle	 it	 branches	 in	 order	 to	 innervate	multiple	 skeletal	 muscle	 fibres,	
which	are	 then	 collectively	 known	as	 a	motor	unit.	Where	 the	axon	 terminal	 reaches	 the	
muscle	membrane	 it	 branches	 again	 and	 loses	 its	myelin	 sheath.	 The	 Schwann	 cells	 then	
associate	 with	 the	 axon	 terminal	 for	 support.	 Active	 zones	 are	 areas	 in	 the	 presynaptic	
terminal	 where	 large	 amounts	 of	 acetylcholine	 (ACh)	 containing	 vesicles	 are	 clustered,	
ready	to	be	released.	
The	 nerve	 and	 muscle	 membrane	 are	 aligned	 tightly	 by	 the	 basal	 lamina	 of	 the	
neuromuscular	junction.	
The	sarcolemma	at	the	neuromuscular	junction	is	corrugated,	forming	invaginations	(folds)	







Action	 potential	 arrival	 at	 the	 motor	 terminal	 depolarises	 the	 prejunctional	 membrane	
adjacent	to	the	active	sites.	2)	Voltage-gated	Ca2+	channels	respond	to	the	depolarisation	by	
opening,	which	results	 in	calcium	influx.	3)	The	resulting	increase	in	calcium	concentration	
acts	 on	 the	 primed	 ACh-containing	 vesicles	 to	 produce	 fusion	 of	 the	 vesicle	 and	 cell	




voltage-gated	 calcium	 channels	 leading	 to	 ACh	 release	 (Figure	 2).	 The	 amount	 of	 ACh	




The	 calcium	 channels	 responsible	 for	 quantal	 (released	 from	 vesicle	 through	 exocytosis)	
transmitter	 release	 in	mammals	are	primarily	of	 the	P-type	 [2-4],	 and	are	 located	directly	
adjacent	to	the	active	zones	[5].	(Figure	1)	






calcium	 channels	 by	 other	 bivalent	 cations	 such	 as	 magnesium	 (as	 well	 as	 the	
aminoglycoside	antibiotics)	can	lead	to	a	reduction	in	the	quanta	of	ACh	released	[7,	8].	
1.1.3.	 	 Vesicle	release	and	recycling	
ACh-containing	vesicles	 in	 the	prejunctional	element	exist	 in	 two	pools	 -	 the	 reserve	pool	
and	the	readily	releasable	pool	(Figure	1).	The	readily	releasable	pool	of	vesicles	are	bound	
to	 the	 active	 zones,	 docked	 and	 primed,	 awaiting	 the	 arrival	 of	 an	 action	 potential.	 The	
vesicles	of	the	reserve	pool	are	bound	to	the	cytoskeleton	of	the	nerve	terminal,	unable	to	
release	their	content	until	they	are	translocated	to	the	active	zones.		
Upon	 action	potential-induced	 calcium	 influx,	 calcium	 is	 sensed	by	 the	 vesicle	membrane	
associated	protein	synaptotagmin,	which	leads	to	fusion	of	the	vesicle	and	cell	membranes	
[7,	 9].	 This	 forms	 a	 pore	 between	 the	 interior	 of	 the	 vesicle	 and	 the	 extracellular	 space,	
allowing	ACh	to	be	expelled	into	the	synaptic	cleft	through	a	process	known	as	exocytosis.	
(Figure	2)	
The	 full	 description	 of	 the	 synaptic	 vesicle	 cycle	 is	 beyond	 the	 scope	 of	 this	 dissertation,	
however	a	comprehensive	review	of	the	underlying	mechanisms	is	described	by	Siegelbaum	
et	al.	[9].	
In	 certain	 conditions,	 such	as	high	 frequency	 stimulation,	 the	 vesicles	of	 the	 reserve	pool	
can	be	called	upon	to	move	into	the	readily	releasable	pool	for	to	replace	depleting	vesicles,	
in	 a	 process	 known	 as	 translocation.	 The	 initial	mechanism	 for	 activating	 translocation	 is	
thought	 to	 be	 mediated	 by	 high	 frequency	 stimulation	 increasing	 intracellular	 calcium	
concentration	 due	 to	 the	 influx	 outcompeting	 efflux.	 This	 leads	 to	 activation	 of	 Ca2+-
dependant	 enzymes	 that	 would	 break	 the	 vesicle-cytoskeletal	 bonds	 allowing	 vesicles	 to	
migrate	and	dock	 into	 the	 readily	 releasable	pool.	Prejunctional	 (nicotinic	and	muscarinic)	
receptors	 [10]	 also	 induce	 translocation	of	 reserve	 pool	 vesicles	 to	 the	 active	 zones,	 as	 a	













the	 postjunctional	 membrane,	 when	 two	 ACh	 molecules	 ( )	 bind	 the	 nAChR	 ( ),	 the	
receptor	ion	channel	opens,	creating	a	MEPP	through	sodium	influx,	which	when	summated	




Propagation	 of	 neuromuscular	 signalling	 is	 primarily	 by	 the	 action	 of	 nicotinic	 cholinergic	
receptors.	
The	nicotinic	cholinergic	receptors	(nAChR)	are	primarily	heterogenic	(made	up	of	multiple	












and	 are	 concentrated	 at	 the	 peaks	 of	 the	 primary	 folds	 of	 the	 muscle	 membrane.	 The	
postsynaptic	nicotinic	receptors	are	those	responsible	mainly	for	the	reception	of	the	neural	
signal	 onto	 the	 muscle	 membrane,	 and	 activation	 of	 which	 is	 generally	 considered	 to	








which	 creates	 short	 lasting	 miniature	 end	 plate	 potentials	 (MEPPs).	 These	 will	 summate	
with	neighbouring	MEPPs	produced	by	 adjacent	 receptors	 to	 form	an	end	plate	potential	
(EPP)	which	will	 propagate	 into	 the	 secondary	 folds	 of	 the	 sarcolemma.	 If	 the	 summated	
EPPs	are	sufficient	to	reach	threshold,	voltage-gated	sodium	channels	in	the	troughs	of	the	
secondary	 folds	 will	 open	 to	 produce	 an	 action	 potential	 that	 propagates	 down	 the	
sarcolemma	and	ultimately	initiates	the	contraction	of	the	muscle	cell	[1].	(Figure	3)	
It	should	noted	that	studies	on	rats	[23]	and	mice	[24]	have	both	shown	selective	blockade	


















subtype	 1	 (M1)	 is	 believed	 to	 facilitatory	 in	 nature,	 by	 activating	 PKC	 and	 PLC	 second	
messenger	 cascades	which	 lead	 to	 an	 increase	 in	 calcium	 currents	 through	 the	 P/Q-type	
VGCCs	[16,	18,	25],	as	well	as	increasing	the	translocation	and	priming	of	vesicles	from	the	






P2Y	 receptor	 appears	 to	be	modulation	of	 non-quantal	 (spontaneous)	 transmitter	 release	
through	phospholipase	C	activation	[11,	26].	
The	A1	and	A2A	receptors	respond	to	adenosine	as	their	ligand.	It	is	known	that	they	function	











One	AChE	enzyme	has	 six	 active	 capable	of	 breaking	down	ACh.	 Each	 site	has	 two	active	
binding	sites	–	namely	the	anionic	and	the	esteratic	sites.	The	quaternary	nitrogen	group	on	
ACh	binds	the	anionic	site,	while	the	esteratic	site	binds	and	forms	a	covalent	bond	with	the	
carbamate	 group	of	ACh.	Within	 100	µs,	 hydrolysis	 of	ACh	has	 occurred	 and	 acetate	 and	
choline	are	release	from	the	active	site	[30].		
AChE	is	one	of	the	most	efficient	catabolic	enzymes	known	to	mankind,	with	most	literature	
citing	 that	 all	 released	ACh	molecules	are	 invariably	broken	down	1	millisecond	after	 it	 is	
released	from	the	nerve	terminal	 [1],	and	 just	under	50%	of	released	ACh	 is	broken	down	
before	it	even	reaches	the	postjunctional	membrane	[31].	
1.1.6.	 	 Safety	margin	of	the	NMJ	
The	 safety	 margin	 (or	 factor)	 of	 the	 neuromuscular	 synapse	 can	 be	 regarded	 as	 “an	
expression	of	how	much	greater	an	effect	the	nerve	has	on	the	muscle	fibre	than	is	required	










Neuromuscular	 block	 (NMB)	 is	 a	 pharmacological	 technique	 whereby	 skeletal	 muscle	
relaxation	is	obtained	through	inhibition	of	neuromuscular	transmission.	
1.2.1.	 	 Indications	
Neuromuscular	 block	 is	 used	 when	 skeletal	 muscle	 relaxation	 is	 needed	 for	 a	 variety	 of	
clinical	 applications.	 The	 most	 common	 use	 is	 prior	 to	 endotracheal	 intubation,	 where	
indicated,	 usually	 at	 induction	 of	 general	 anaesthesia.	 Relaxation	 is	 usually	maintained	 in	
order	to	allow	smooth	mechanical	ventilation	of	the	lungs	during	surgery	or	in	the	intensive	
care	 unit.	 Neuromuscular	 block	 additionally	 provides	 favourable	 operating	 conditions	 for	
surgery,	 such	 as	 lack	 of	 abdominal	 muscle	 tone	 for	 laparoscopic	 procedures	 [33]	 or	
orthopaedic	 surgery	 [34].	 It	 also	 can	 be	 used	 to	 suppress	 any	 muscle	 movements	 for	
delicate	 procedures	 for	 example	 as	 seen	 in	 ophthalmology,	 although	 it	 should	 be	
emphasised	that	neuromuscular	block	is	never	a	replacement	for	balanced	anaesthesia.		
1.2.2.	 	 Classification	






















The	non-depolarising	neuromuscular	 blockers	 are	 competitive	 antagonists	 of	 the	nicotinic	
cholinergic	receptors,	primarily	of	those	found	in	the	neuromuscular	junction.	By	acting	as	
an	 antagonist	 to	 even	 one	 of	 the	 binding	 sites,	 the	 receptor	 is	 prevented	 from	 being	
activated	 even	 if	 ACh	 occupies	 the	 other	 binding	 site.	 This	 makes	 the	 neuromuscular	
blockers	 antagonists	 of	 the	 nicotinic	 cholinergic	 receptors.	 Binding	 of	 NMBA	 to	 the	
postjunctional	 receptors	 is	 probably	 the	 most	 important	 mechanism	 to	 produce	
neuromuscular	block	[35].	On	the	other	hand,	it	should	be	noted,	that	a	large	proportion	of	
the	postsynaptic	receptors	(70-75%)	could	be	blocked,	with	no	measureable	impairment	of	
neuromuscular	 transmission	 [36].	 This	 however	 reflects	 the	 high	 safety	 factor	 of	
neuromuscular	transmission	rather	than	the	potency	of	the	NMBA.	
Binding	of	 the	NMBAs	has	been	 shown	 in	 vitro	 on	Xenopus	 laevis	 oocytes	 expressing	 the	
prejunctional	 nAChRs	 [37].	 This	 is	 often	 cited	 as	 the	mechanism	 by	which	 fade	 of	 twitch	
height	was	observed	during	repetitive	stimulation.	However,	despite	evidence	of	binding	to	
the	 receptor,	 selective	 blockade	 of	 the	 prejunctional	 nAChRs	 was	 not	 able	 to	 produce	












In	 order	 for	 an	 anaesthetist	 to	 responsibly	 administer	 a	 balanced	 anaesthetic	 (including	
muscle	relaxation),	the	depth	of	NMB	should	be	able	to	be	deepened	or	maintained	prior	to	
functional	 recovery	 of	 muscle	 tone	 or	 spontaneous	 breathing,	 which	 might	 otherwise	
provide	 unfavourable	 operating	 conditions	 for	 the	 surgeon	 [33].	 Additionally,	 most	 NMB	
reversal	agents,	 in	order	to	be	most	effective,	should	be	administered	only	after	a	certain	
degree	 of	 spontaneous	 recovery	 from	NMB	 [39,	 40].	 Following	 reversal,	 it	would	 also	 be	
prudent	 to	 ensure	 the	 neuromuscular	 transmission	 had	 recovered	 to	 a	 satisfactory	 level	
prior	 to	extubation,	 and	before	discharge	 to	 the	post-anaesthesia	 care	unit	 (PACU).	All	 of	
these	scenarios	require	us	to	be	able	to	measure	depth	of	neuromuscular	block.	
1.3.1.	 	 Methods	of	neuromuscular	monitoring	
There	 are	 three	 generally	 accepted	 categories	 of	 neuromuscular	 monitoring	 measures:	
clinical	 measures	 of	 muscle	 weakness	 (clinical	 neuromuscular	 monitoring),	 qualitative	
measurement	 of	 evoked	 muscle	 twitches	 (qualitative	 neuromuscular	 monitoring)	 and	




speak,	or	perform	a	sustained	head	 (or	 leg)	 lift	 for	 five	seconds.	A	study	by	Cammu	et	al.	
[41]	 clearly	 illustrates	 the	 inadequacies	 of	 these	measures	 in	 their	 sensitivity,	 specificity,	
positive	and	negative	predictive	values.	Despite	these	findings,	the	use	of	clinical	measures	






These	 methods	 work	 on	 the	 principle	 of	 a	 controlled	 stimulation	 of	 a	 peripheral	 nerve	









used	 in	qualitative	monitoring.	 Fade	 in	 the	muscle	 twitch	 response	 to	Train-of-Four	 (TOF)	
stimulation	(discussed	below),	tetanic	stimulation	and	double	burst	stimulation	are	all	used	
to	 evaluate	moderate	 to	mild	 neuromuscular	 block.	 Inconsistency	 in	 the	 ability	 to	 detect	
fade	 (by	 these	methods)	 at	 clinically	 relevant	 depths	 of	 neuromuscular	 block	 (TOF-R<0.9)	
has	 been	 demonstrated	 in	 many	 studies	 [49-55],	 illustrating	 the	 unreliability	 of	 these	
subjective	measures.		
1.3.1.2.2.	 Quantitative	neuromuscular	monitoring	
The	 use	 of	 transducers	 to	 measure	 the	 magnitude	 of	 the	 muscle	 response	 to	 nerve	
stimulation	has	grown	to	become	the	standard	for	neuromuscular	monitoring.	This	is	most	
likely	 due	 to	 the	 lack	 of	 variability	 compared	 to	 qualitative	 measures,	 as	 well	 as	 the	
objective	values	that	can	be	used	as	guides	to	timing	of	reversal	and	extubation.	
1.3.1.2.2.1.	 Method	of	twitch	detection	
There	 are	multiple	methods	 of	 detecting	 the	 evoked	muscle	 twitch	 produced	 from	nerve	
stimulation,	 all	 of	 which	 vary	 in	 their	 reliability,	 practicality	 and	 ease	 of	 use.	Within	 the	




electromyography	 (EMG)	 and	 acceleromyography	 (AMG)	 will	 be	 discussed,	 however	













muscles	 that	 are	 produced	 by	 nerve	 stimulation.	 Its	 advantages	 include	 the	 ability	 to	
measure	from	a	much	larger	variety	of	muscles,	not	requiring	a	preload	to	the	muscle	and	
relatively	 compact	 and	 quick	 setup.	 Disadvantageous	 include	 the	 need	 for	 thorough	












neuromuscular	 block	 decreasing	with	 smaller	muscle	movements	 [58].	Most	modern	 day	
neuromuscular	 monitoring	 devices	 utilise	 this	 method	 (e.g.	 TOF	 Watch®,	 Organon,	
Roseland,	NJ,	USA).	
1.3.1.2.2.2.	 Stimulation	patterns	and	measures	
The	 use	 of	 different	 stimulation	 parameters	 and	 measures	 allows	 detection	 of	 different	









of	 the	 baseline	 value	 (%T1).	 While	 suppression	 of	 T1	 is	 a	 good	 indicator	 of	 moderate	
neuromuscular	 block,	 it	 is	 insufficient	 to	 detect	 shallow	 or	 residual	 neuromuscular	 block.	









2	 seconds).	 This	 train	 can	 be	 repeated	 at	 intervals	 of	 every	 15	 seconds	 or	 longer,	 or	




index	 of	 neuromuscular	 transmission.	 It	 is	 generally	 considered	 that	 TOFfade	 is	 a	
prejunctional	phenomenon	due	 to	 reduced	ACh	 release	upon	each	 stimulation	 [1,	 21,	 35,	
59,	60].	Blockade	of	the	prejunctional	cholinergic	receptors	would	inhibit	the	facilitation	of	
translocation	of	ACh	vesicles	 from	the	reserve	pool	 to	the	active	zone,	 thus	making	 fewer	
cholinergic	vesicles	available	for	release	with	each	subsequent	twitch	of	the	train.		
However,	 recent	 in	 vivo	 studies	 in	 rodents	 have	 shown	 that	 selective	 antagonists	 of	








hypoxic	 ventilatory	 drive	 and	 profound	 muscle	 weakness	 symptoms	 at	 a	 TOF-R	 of	 0.7,	








reflecting	 the	 safety	margin	 of	 the	 NMJ	 [36],	 and	 thus	 recovery	 to	 0.9	 (or	 90%	 as	 often	
stated)	does	not	imply	90%	removal	of	the	NMBA	from	the	NMJ.	
1.4.	 	 Neuromuscular	block	reversal	
Given	 neuromuscular	 block’s	 exclusive	 need	 to	 facilitate	 optimal	 surgical	 operating	 and	
ventilation	conditions,	its	presence	postoperatively	is	generally	unnecessary,	unpleasant	for	
the	patients	and	potentially	harmful.	Therefore,	after	NMB	 is	no	 longer	needed,	methods	












Figure	5:	Mechanism	of	AChE	 inhibitor-induced	 reversal	of	NMB.	 (A)	 Prior	 to	 reversal	 the	
NMBA	 ( )	 dominates	 the	 competitive	 occupation	 of	 the	 postjunctional	 nAChR.	 (B)	
Inhibition	of	the	catabolic	enzyme	of	ACh	by	neostigmine	( )	leads	to	an	accumulation	(and	








The	 discovery	 that	 inhibition	 of	 the	 enzyme	 AChE	 could	 antagonise	 the	 neuromuscular	
impairment	of	curare-like	drugs	was	first	described	in	an	in	vivo	frog	model	[62].	
Suppression	of	AChE’s	activity	leads	to	a	reduction	in	the	breakdown	of	ACh,	thus	elevating	
the	 concentration	 of	 ACh	 in	 the	 neuromuscular	 cleft.	 This	 elevated	 concentration	makes	
ACh	 competitive	 for	 binding	 to	 the	 receptor,	 effectively	 displacing	 the	 NMBA	 from	 the	
binding	 site,	 and	 thus	 reinstating	neuromuscular	 transmission.	Drugs	 such	as	neostigmine	
and	 pyridostigmine	 (being	 oxydiaphoretic	 AChE	 inhibitors)	 mimic	 ACh	 in	 their	 binding,	
however	the	covalent	bond	formed	is	stronger	than	that	formed	with	ACh.	This	 leads	to	a	
vastly	longer	occupation	of	the	active	site	(neostigmine’s	half-life	of	binding	to	AChE	can	be	
in	 the	 order	 of	 7	minutes).	 During	 this	 time	ACh	 cannot	 be	 bound	 or	 broken	 down,	 thus	
elevating	its	junctional	concentration	[40].	(Figure	5)	
It	 is	 important	 to	 note	 that	 this	mechanism	 does	 not	 increase	 the	 removal	 of	 the	NMBA	
from	 the	 neuromuscular	 junction	 [30].	 Any	 alteration	 of	 ACh	 concentration	 after	 AChE	
inhibitor	 reversal	 could	 potentially	 allow	 the	 NMBA	 to	 rebind	 the	 receptor	 and	 reinstate	
NMB.	
Due	 to	 the	 AChE	 inhibitor’s	 inability	 to	 inhibit	 ACh	 breakdown	 at	 the	 NMJ	 selectively,	
cholinergic	transmission	is	elevated	systemically,	with	the	exception	of	the	central	nervous	
system,	as	the	agents	used	for	neuromuscular	block	reversal	are	not	able	to	penetrate	the	











The	 discovery	 that	 neuromuscular	 block	 could	 be	 reversed	 through	 encapsulation	 and	
binding	of	a	NMBA	was	first	described	in	2002	[63,	64].	
The	 exact	 pharmaco-chemical	 interactions	 that	 underlie	 the	 encapsulation	 and	binding	of	
the	 steroidal	NMBA	are	 covered	 in	 detail	 by	 Epemolu	 et	 al.	 [64],	 as	 they	 are	 beyond	 the	
scope	of	this	study.		
Selective	 encapsulation	 and	 irreversible	 binding	 of	 rocuronium	 (and	 other	 aminosteroid	




plasma	bound	receptor	 that	 is	able	 to	draw	the	neuromuscular	blocking	agent	away	 from	
the	nicotinic	 receptors	 (i.e.	 substantially	 lowering	 the	 concentration	of	 rocuronium	 in	 the	
NMJ).	 This	 allows	 restoration	 of	 neuromuscular	 transmission	 by	 reinstating	 ACh’s	
competitive	binding	to	the	nicotinic	receptors,	without	altering	its	concentration	in	the	NMJ.	
(Figure	6)		
It	 should	 however	 be	 emphasised	 that	 in	 order	 to	 reverse	 neuromuscular	 block	
satisfactorily,	not	every	molecule	of	 rocuronium	needs	 to	bound	by	 sugammadex	or	even	
extracted	 from	 the	 NMJ.	 Only	 enough	 rocuronium	 needs	 to	 be	 bound	 to	 reduce	 the	











Figure	 6:	 The	 mechanism	 of	 sugammadex	 reversal	 of	 rocuronium	 neuromuscular	 block.	
After	 sugammadex	 ( )	 is	 administered,	 rocuronium	 in	 the	 intravascular	 compartment	 is	
encapsulated	 and	 bound.	 This	 creates	 a	 rocuronium	 concentration	 gradient	 between	 the	






required.	 rNMB	 can	 thus	 be	 defined	 as	 an	 impairment	 of	 neuromuscular	 transmission	




would	 allow	 extubation	 and/or	 discharge	 to	 the	 PACU	 of	 the	 patient	 with	 a	 degree	 of	
confidence	in	the	recovery	from	neuromuscular	block.	














A	 multicentre	 study	 in	 Portugal	 conducted	 in	 2013	 reported	 an	 incidence	 of	 26%	 in	 the	
PACU	[72].	A	2015	Canadian	multicentre	study	reported	rNMB	to	occur	in	68.5%	and	56.5%	
of	 patients	 at	 time	 of	 extubation	 and	 time	 of	 arrival	 at	 the	 PACU	 respectively	 [73].	 A	
prospective	 audit	 of	 64	 children	 who	 received	 NMBAs	 in	 an	 Australian	 tertiary	 hospital	
found	 rNMB	 incidence	 to	 be	 28.1%	 [74].	 An	 observational	 study	 of	 415	 patients	 who	
received	 intermediate-acting	 NMBAs	 in	 2010	 observed	 a	 rNMB	 incidence	 of	 43%	 [47].	 A	
multicentre	observational	 Chinese	 study	of	 1571	adult	 patients	 showed	 rNMB	 to	have	an	
incidence	of	57.8%	[75].	
1.5.2.	 	 Risk	factors/causes	
The	 absolute	 risk	 factor	 for	 rNMB	 is	 obviously	 the	 use	 of	 NMBA.	 A	 landmark	 study	 of	
599,548	surgical	patients	between	1948	and	1952	found	that	mortality	rates	were	increased	
six-fold	with	the	use	of	NMBA	[76],	which	since	then	has	almost	certainly	been	attributed	to	













TOF-R.	 The	 recommended	 guidelines	 for	 dosing	 of	 neostigmine	 are:	 0.07	mg/kg	 at	 a	 TOF	
count	of	2	or	3	and	0.04	–	0.05	mg/kg	at	TOF-R	>	0.4.	It	is	recommended	that	at	a	TOF-R	>	
0.7,	pharmacological	 reversal	 is	omitted,	due	 to	 the	 risk	of	AChE-inhibition	 impairment	of	
neuromuscular	transmission	[40].	According	to	the	dose	recommendations	provided	by	the	
manufacturer,	sugammadex	dosing	is	as	follows:	2	mg/kg	at	a	TOF	count	>	2,	4	mg/kg	at	1	–	
2	 post-tetanic	 counts	 and	 TOF	 count	 =	 0	 and	 16	 mg/kg	 for	 reversal	 of	 rocuronium	
immediately	after	IV	administration	[78].		
The	class	of	reversal	agent	used	appears	to	play	a	role	in	rNMB.	Sugammadex	reversal	has	




to	 anaesthetic	 complications	 [76,	 80,	 81].	 It	 was	 revealed	 that	 respiratory	 complications,	
such	 as	 respiratory	 depression	 or	 arrest	 and	 upper	 airway	 obstruction,	 are	 among	 the	
largest	 contributors	 to	 these	 postoperative	 events.	 As	 discussed	 above,	 the	 incidence	 of	
rNMB	 has	 been	 found	 to	 be	 high	 (although	 this	 varies	 from	 study	 to	 study)	 in	 the	
postoperative	 recovery	 room	 and	 theorised	 to	 be	 the	 major	 contributing	 factor	 [61].	
Inadequate	 respiratory	 ventilation	 and	 impaired	 pharyngeal	 function	 are	 dangerous	
conditions	in	the	postoperative	period	(especially	if	the	patient	has	already	been	extubated,	
and	 airway	 protection	 is	 diminished),	 and	 can	 lead	 to	 hypoxia	 and	 aspiration	 pneumonia	
respectively.	 In	 addition	 to	 respiratory	 weakness,	 generalised	 skeletal	 muscle	 weakness	










need	 for	 top	up	of	NMBA)	 and	 the	 appropriate	 reversal	 of	NMB	 -	 i.e.	 appropriate	dosing	








The	Mg2+	 ion	 is	 the	 fourth	most	 common	 cation	 in	 the	 body,	 and	 second	most	 common	
intracellularly.	 Less	 than	1%	of	all	magnesium	 in	 the	body	 (total	body	magnesium	–	TBM)	
however	 is	 found	 circulating	 in	 the	 blood	 -	 dissolved	 in	 serum	 (0.3%	 of	 TBM)	 or	 within	
erythrocytes.	Serum	magnesium	can	either	be	ionised	(62%	of	serum	Mg2+),	plasma	protein	
bound	(33%	of	serum	Mg2+)	or	bound	to	serum	anions	(5%	of	serum	Mg2+).	The	remaining	
magnesium	 is	 within	 the	 bone	 (53%	 of	 TBM)	 and	 the	 intracellular	 fluid	 (46%	 of	 TBM).	













[99]	 and	 Jenkinson	 [100]	 on	 the	 frog	 sartorius	 nerve-muscle	 preparation	 showed	 that	
magnesium	produced	a	decrease	 in	ACh	 release	by	 competitively	 inhibiting	 calcium	 influx	
into	the	prejunctional	terminal.	
Further	 studies	 have	 also	 illustrated	 impairment	 in	 neuromuscular	 transmission	 (or	
neuromuscular	 block)	 with	 intravenous	 magnesium	 sulphate,	 as	 seen	 in	 a	 guinea	 pig	




produced	 certain	 members	 of	 the	 aminoglycoside	 class	 of	 antibiotics	 is	 mediated	 by	




with	 repetitive	 nerve	 stimulation	 (fade)	 to	 reduced	 Ca2+	 influx,	 which	 in	 turn	 lowers	 the	
probability	of	vesicle	release.		
Taken	together,	it	would	be	reasonable	to	assume	that	the	depression	of	ACh	release	(and	




were	 described	 as	minor	 compared	 to	 its	 prejunctional	 effects	 [99,	 100].	 	 A	more	 recent	
study	 by	Wang	 et	 al.	 possibly	 explains	 the	 inhibitory	 effect	 on	 postjunctional	 potentials.	
They	 were	 able	 to	 demonstrate	 that	 magnesium	 decrease	 the	 conductance	 of	 the	
postjunctional	nAChR	to	the	depolarising	action	of	ACh	[111]	using	an	 in	vitro	patch-clamp	





clinically	 were	 needed	 to	 produce	 relatively	 low	 inhibition	 of	 conductance	 (6mmol/L	 to	
produce	20%	inhibition).	
1.6.2.	 	 Interaction	with	NMBAs	
Magnesium’s	 ability	 to	 potentiate	 the	 neuromuscular	 blocking	 effects	 of	 the	 curare-like	
drugs	 is	 also	 well	 documented;	 including	 shortening	 the	 duration	 of	 onset	 [112,	 113],	
prolonging	recovery	[91,	92,	94]	and	reinstating	NMB	[89,	90,	93,	95].	
The	patch-clamp	study	mentioned	above,	by	Wang	et	al.,	 found	magnesium	to	potentiate	




It	 is	 already	 a	 component	 of	 nearly	 every	 living	 thing	 (including	 humans),	 meaning	
hypersensitivity	is	‘impossible’.		
The	human	body	has	already	developed	physiological	mechanisms	to	increase	elimination	of	
the	 ion	 through	 renal	 filtration,	 thus	 when	 administered	 in	 excess,	 excretion	 can	 be	
increased	accordingly.		
Clinically	 relevant	 side	 effects,	 as	 a	 result	 of	 hypermagnesaemia,	 only	 begin	 to	 appear	 at	
plasma	 concentrations	 of	 5	mmol/L,	well	 above	 the	 therapeutic	 range	 of	 2	 -	 3.5	mmol/L	
[114].	These	include	muscle	(including	respiratory)	weakness	and	CNS	depression	at	plasma	
concentrations	between	6	–	8	mmol/L	and	 cardiac	 conduction	abnormalities	 at	7	mmol/L	
[115].	 It	 should	 however	 be	 noted	 that	 these	 toxicity	 levels	 are	 when	 magnesium	 is	
administered	alone.	Muscle	weakness	would	most	likely	be	observed	at	lower	plasma	levels	
in	the	presence	of	NMBAs	or	aminoglycoside	antibiotics.	









variety	 of	 indications	 for	 which	 oral	 administration	 is	 applicable,	 this	 section	 will	 briefly	
focus	on	some	of	the	conditions	for	which	intravenous	magnesium	therapy	is	used	that	are	
applicable	to	the	perioperative	period.	
The	most	common	use	of	 intravenous	magnesium	 is	 in	 the	management	of	pre-eclampsia	
and	eclampsia,	for	which	it	is	the	first	line	treatment	[117].	Target	therapeutic	plasma	levels	
for	 management	 of	 eclampsia	 is	 2	 -	 3.5	 mmol/L	 and	 is	 usually	 given	 as	 an	 intravenous	
infusion	of	4	–	6	g	over	15-20	minutes,	followed	by	1	–	4	g/h	[114].	
The	 use	 of	magnesium	 sulphate	 in	 the	 anaesthetic	management	 of	 phaeochromocytoma	
resection	 was	 first	 described	 in	 1985	 by	 James	 [118].	 Successful	 use	 of	 magnesium	 in	
phaeochromocytoma	 resections	 has	 continued	 to	 be	 reported	 by	 James	 [119-122]	 and	
others	[123-127].	
Magnesium	 has	 also	 been	 shown	 to	 be	 effective	 in	 the	 treatment	 of	 certain	 cardiac	
arrhythmias	 (especially	 in	 the	 perioperative	 period)	 such	 as	 torsade	 de	 pointes	 [128-134]	
and	atrial	fibrillation	[135-137].	
Additional	 uses	 for	 magnesium	 infusion	 include:	 hemodynamic	 control	 during	 intubation	




Recurarisation	 is	 a	 reinstatement	 of	 neuromuscular	 block,	 after	 a	 degree	 of	 recovery	 (or	
reversal)	of	neuromuscular	transmission.	Although	there	are	many	possible	mechanisms	to	
produce	recurarisation,	 incidents	described	in	the	 literature	are	mostly	drug	 induced,	with	





Another	 possible	 mechanism	 of	 recurarisation	 is	 if	 a	 long-acting	 NMBA	 is	 reversed	 with	







A	 case	 report	 published	 in	 the	 British	 Journal	 of	 Anaesthesia	 (2003),	 also	 reported	
recurarisation	 after	 magnesium	 administration	 in	 a	 neostigmine/glycopyrrolate-reversed	
patient	[90].		
Magnesium	 recurarisation	 following	 sugammadex	 reversal	 was	 described	 following	 what	
can	be	considered	inadequate	dosing	of	reversal	and	overdose	of	magnesium.		In	an	in	vivo	
guinea-pig	model,	 rocuronium	was	 reversed	with	 330	nmol/kg	 (approximately	 0.7	mg/kg)	
sugammadex	to	a	%T1	of	99%	and	was	followed	by	86.6	mg/kg	of	magnesium	sulphate.	This	
produced	 a	 decrease	 in	 %T1	 of	 97%.	 	 Ninety	 percent	 recovery	 was	 obtained	 after	 34	
minutes	post-magnesium	 injection.	This	effect	 could	be	 reduced	 to	a	 reduction	of	21%	of	
%T1,	 and	 recovery	 after	 13	 minutes,	 by	 increasing	 the	 dose	 of	 sugammadex	 used	 for	
reversal	 two-fold	 [110].	 This	 dose	 of	 magnesium	 used	 was	 far	 greater	 and	 the	 doses	 of	
sugammadex	substantially	less	than	those	used	in	our	study.	
A	 20-person	 study	 published	 in	 the	 European	 Journal	 of	 Anaesthesiology	 showed	
magnesium	 recurarisation	 after	 a	 dose	 of	 50	 mg/kg	 administered	 at	 a	 TOF-R	 of	 0.9	 in	




Unterbachner	 et	 al.	 published	 a	 case	 report	 wherein	 they	 reported	 magnesium	









magnesium	 sulphate	 after	 reversal	 of	 rocuronium	 neuromuscular	 block	 with	 either	
sugammadex	 (2	 mg/kg)	 or	 neostigmine/glycopyrrolate,	 and	 showed	 no	 significant	
differences	between	the	reversal	groups	[155].	The	results	of	this	study	were	perplexing	at	
the	 time,	 as	 a	 lack	 of	 recurarisation	 was	 expected	 in	 sugammadex-reversed	 rats,	 on	 the	
basis	of	the	sugammadex	mechanism	of	removing	residual	rocuronium.	
1.7.	 	 Problem	identification	
Presently,	 there	 are	 no	 controlled	 animal	 studies	 comparing	 magnesium	 recurarisation	




However,	due	 to	 the	unexpected	 result	observed	 in	 the	previous	 study,	 certain	questions	
were	raised	that	brought	into	question	the	validity	of	data:		
Was	the	dose	of	magnesium	administered	(30	mg/kg)	perhaps	sufficiently	high	to	produce	
neuromuscular	 impairment	 itself,	 instead	 of	 the	 result	 of	 reinstatement	 of	 rocuronium	
NMB?	 The	 highest	 intravenous	 dose	 of	 magnesium	 sulphate	 that	 did	 not	 produce	
detectable	 neuromuscular	 impairment	 in	 the	 absence	 of	 NMBA	 would	 need	 to	 be	
determined.		
Was	the	dose	of	sugammadex	used,	albeit	the	standard	dose,	not	high	enough	to	sequester	
all	 the	rocuronium	from	the	NMJ?	 If	 the	dose	used	 for	 reversal	was	 increased,	would	 this	
result	in	a	reduction	in	the	magnitude	of	the	recurarisation	effect.	
In	order	to	fully	characterise	magnesium	recurarisation,	 it	was	believed	to	be	necessary	to	









To	 investigate	 the	 neuromuscular	 effects	 of	 a	 range	 of	 intravenous	magnesium	 sulphate	
doses,	 in	 the	 absence	 of	 NMBAs,	 in	 this	 rat	 model	 of	 neuromuscular	 transmission,	 and	
determine	the	highest	dose	that	does	not	produce	detectable	neuromuscular	depression.		
1.8.2.	 	 Magnesium	recurarisation	between	reversal	regimes	







H0:	 Increasing	 dose	 of	 intravenous	 magnesium	 sulphate	 produces	 no	 observable	
depression	of	neuromuscular	transmission	
H1:	 Increasing	 dose	 of	 intravenous	 magnesium	 sulphate	 produce	 a	 dose-dependant	
depression	of	neuromuscular	transmission	
1.9.2.	 	 Magnesium	recurarisation	experiment	

















• Isoflurane		 	 	 	 	 Isofor®,	Safeline	Pharmaceuticals	
• Sodium	Pentobarbitone	200	mg/mL			 Euthanaze	®,	Bayer	Healthcare	
• Neostigmine	Methylsulphate	0.5	mg/mL		 Bodene	
• Glycopyrrolate	0.2	mg/mL		 	 	 Robinul®,	Bodene	
• Magnesium	Sulphate	50%	Solution		 	 Kyron	Laboratories	
The	University	of	Cape	Town,	Department	of	Anaesthetics,	donated	the	following:	
• Rocuronium	Bromide	10	mg/mL		 	 Esmeron®,	MSD	




















it	was	 stored	at	5oC.	 The	 syringe	was	 removed	 from	 the	 fridge	approximately	10	minutes	
prior	 to	 its	 anticipated	 injection,	 to	 allow	 it	 to	 equilibrate	 with	 room	 temperature.	
Rocuronium	was	 prepared	 on	 the	 day	 of	 use	 and	 any	 unused	 prepared	 rocuronium	was	
discarded	10	hours	after	dilution.	Stock	vials	of	rocuronium	were	stored	at	5oC	according	to	
manufacturers	guidelines.		
1	 mL	 of	 sugammadex	 (4	 mg/mL	 or	 16	 mg/mL)	 was	 prepared	 in	 0.9%	 saline	 in	 a	 1.5	 mL	
labelled	eppendorf	and	drawn	up	into	a	1	mL	syringe	at	 least	3	hours	prior	to	intravenous	
injection	and	 stored	at	 room	 temperature.	 Sugammadex	was	prepared	on	 the	day	of	use	
and	any	unused	sugammadex	was	discarded	10	hours	after	dilution.	
2.2.	 	 Animals	
Male	 Sprague-Dawley	 (SD)	 rats	were	 used	 in	 this	 study	weighing	 between	 280	 and	 400g.	
Rats	were	 housed	 under	 standard	 laboratory	 rat	 husbandry	 conditions	with	 a	 12-h	 light–
dark	cycle	(100	–	300	lux)	and	allowed	free	access	to	commercial	pellet	food	and	tap	water.		
To	 limit	possible	confounding	effect	of	hormonal	fluctuations	during	the	females’	four-day	
oestrus	 cycle,	 and	 to	 reduce	 uncontrolled	 variables,	 only	male	 SD	 rats	 were	 used	 in	 this	
study.	
6	rats	were	used	to	refine	surgical	technique	and	characterise	use	of	new	and/or	modified	
equipment.	 25	 rats	 were	 used	 for	 the	 magnesium	 dose-effect	 experiment.	 25	 rats	 were	
used	for	magnesium	recurarisation	experiment.	













gas	 flow	meter	 (Figure	 7:	 C).	 Actual	 isoflurane	 concentration	 from	 vaporiser	 output	 was	
measured	 using	 an	 infrared	 anaesthetic	 gas	 analyser	 (Vamos,	 Dräger,	 Lübeck,	 Germany)	
(Figure	7:F).	Induction	of	anaesthesia	was	rapid	and	judged	by	the	loss	of	the	righting	reflex,	
upon	which	the	rat	was	quickly	removed	from	the	induction	chamber	and	transferred	to	the	
surgical	platform,	placed	on	 it’s	back,	with	 it’s	head	placed	within	a	nose	 cone	–	 through	
which	 anaesthesia	 was	 maintained	 (Figure	 7:	 J).	 The	 isoflurane	 dose	 was	 titrated	 to	 the	
surgical	plane	of	anaesthesia,	judged	by	loss	of	the	pedal	withdrawal	reflex.	The	rat’s	body	
temperature	was	maintained	by	a	 thermostatically	 controlled	heating	plate	 (set	at	37	 oC).	














Andis	 Professional,	 Sturtevant,	 WI,	 USA).	 A	 midline	 incision	 was	 made	 along	 the	 ventral	
surface	 of	 the	 neck.	 Blunt	 dissection	 of	 fascia	 and	 sharp	 dissection	 of	 the	 sternohyoid	
muscle	 was	 used	 to	 expose	 and	 visualise	 the	 trachea.	 Using	 silk	 thread,	 (CliniSilk	 3/0,	
CliniSut,	Port	Elizabeth,	South	Africa)	a	loose	fitting	ligature	was	placed	around	the	trachea	
for	quick	securing	of	the	tracheostomy	tube,	and	a	selection	of	polypropylene	tracheostomy	
tubes	 (made	 in-house,	 Department	 of	 Human	 Biology,	 Cape	 Town,	 South	 Africa)	 were	
prepared	beforehand	and	matched	to	the	size	of	the	trachea.	An	adapted	18G	cannula	was	
inserted	 into	 the	 tracheostomy	tube	 to	act	as	an	 introducer	 for	 insertion.	An	 incision	was	








The	 stroke	 volume	 settings	 for	 average	 rat	 size	 used	 in	 this	 model	 were	 determined	 by	








Figure	7:	 Flow	Diagram	 to	 show	Oxygen-Isoflurane	gas	 flow	 setup	used	 for	 induction	and	
maintenance	of	anaesthesia.	Oxygen	cylinder	(A)	supplying	oxygen	to	anaesthetic	vaporiser	
(D)	 through	 regulator	 (B)	 and	 gas	 flow	 meter	 (C).	 Tap	 1	 (E)	 directs	 a	 portion	 of	 the	
anaesthetic-oxygen	mixture	to	either	the	anaesthetic	gas	analyser	(F)	while	the	remainder	
goes	on	to	Tap	2	(G).	Tap	2	directs	either	to	the	induction	chamber	(H)	or	to	Tap	3	(I),	which	
directs	 the	 mixture	 to	 either	 the	 nose	 cone	 (J)	 or	 the	 animal	 ventilator	 (K).	 The	 animal	















































apparatus.	 (C)	This	secured	the	tracheostomy	 in	place,	but	allowed	free	movement	of	 the	
rat	 during	 procedures	 and	 into	 the	 experimental	 box	 without	 disturbing	 mechanical	
ventilation.	
2.3.3.	 	 Femoral	vein	cannulation	
Hair	over	 the	ventromedial	 surface	of	 the	right	hind	 limb	was	removed	using	a	veterinary	
grade	hair	trimmer.	An	incision	was	made	along	the	ventral	surface	of	the	right	hind	limb,	






ligature.	The	 incision	was	closed	with	 interrupted	sutures	using	3/0	silk	suture	 in	order	 to	














groin	 and	 extended	 laterally	 towards	 the	 lower	 leg.	Muscle	 separation	was	 performed	 to	
expose	 the	sciatic	nerve	 in	 the	gluteal	 space.	The	electrodes	were	hooked	over	 the	nerve	






Figure	 10:	 Sciatic	 nerve	 electrodes	 placed	 and	 secured	 to	 underlying	 muscle	 with	 silk	
sutures.	
2.3.5.	 	 Tendon	isolation	
The	 left	 common	calcaneal	 tendon	was	exposed	and	securely	 ligated	with	3-0	 silk	 thread.	
Ensuring	 secure	 tying	 of	 the	 ligature	 was	 crucial	 to	 prevent	 slipping	 of	 the	 ligature	 once	
connected	 to	 the	 force	 transducer	 and	 applied	 with	 a	 preload.	 The	 tendon	 was	 severed	
distally	to	the	ligature	and	freed	from	immediate	surrounding	tissue.	
2.3.6.	 	 Transfer	and	Setup	
Once	all	 surgical	procedures	had	been	completed	 the	 rat	was	 transferred	 to	a	 specifically	
constructed	 box	 housing	 the	 strain	 gauge	 force	 transducer	 (Human	 Biology	 Electronics	
Workshop).	 (Figure	 11:	 A)	 The	 tendon	 was	 attached	 to	 the	 strain	 gauge	 needle	 by	 the	
ligature.	A	 20G	needle	was	 inserted	 through	 the	 tendon	 capsule	 of	 the	 knee	 joint,	which	










rat	 to	 experimental	 box	 –	 showing	 securing	 of	 the	 tracheostomy	 apparatus	 to	 the	 box,	
attachment	 of	 the	 ligature	 to	 the	 strain	 gauge,	 stimulus	 isolation	 unit	 connecting	 leads	
attached	to	electrodes	and	ECG	electrodes	set	up	in	a	Lead	I	orientation.	
2.3.7.	 	 Train-of-Four	stimulation	
The	 GRASS	 stimulator	 was	 set	 to	 deliver	 Train-of-Four	 (TOF)	 stimulations	 (Figure	 12:	 A)	




amplifier	 (Department	 of	Human	Biology	 Electronics	Workshop),	which	was	 connected	 to	
the	 Powerlab	Unit	 (Model	 26T,	 ADInstruments)	 for	 recording	 by	 LabChart	 7	 Pro	 software	
(ADInstruments).	 Detection	 settings	 and	 Channel	 calculation	 were	 set	 up	 to	 generate	
optimum	 muscle	 twitch	 recordings	 and	 real-time	 Train-of-Four	 Ratio	 (Figure	 12:	 B)	
calculations.	Muscle	tension	was	adjusted	using	a	ratchet	mechanism	attached	to	the	strain	










Figure	 12:	 Train-of-Four	 stimulation	 and	 calculations	 (A)	 Train-of-Four	 nerve	 stimulation	
parameters.	 Train	 stimulation	 was	 repeated	 every	 20	 seconds.	 [picture	 taken	 from:	
http://symbiosbilling.com]56	(B)	Equation	for	calculation	of	the	Train-of-Four	Ratio.		
2.3.8.	 	 Electrocardiogram	(ECG)	/	Heart	Rate	Calculations	
A	 three	 lead	 ECG	 was	 set	 up	 using	 needle	 electrodes	 inserted	 into	 the	 foot	 pads	 and	
connected	 to	 the	 BioAmp	 port	 of	 the	 Powerlab.	 (Figure	 11:	 B)	 ECG	 was	 analysed	 using	
LabChart	 Pro	 ECG	 Analysis	Module	 (ADInstruments)	 to	 generate	 a	 5	 beat-averaged	 heart	
rate,	from	ECG	Lead	II,	in	real	time.		A	baseline	heart	rate,	during	confirmed	surgical	plane	of	
anaesthesia,	was	calculated	based	on	a	5	minute	ECG	trace.	Greater	than	10%	increase	from	
the	 baseline	 value	 was	 used	 as	 an	 indicator	 for	 inadequate	 depth	 of	 anaesthesia,	 in	 the	
period	where	neuromuscular	block	was	present	 thus	 suppressing	any	visible	pain	 reflexes	
(for	e.g.	pedal	twitches).	Additionally	a	heart	rate	alarm	was	set	up	to	alert	when	heart	rate	
increased	 above	 10%	 of	 the	 baseline	 rate,	 and	would	 signal	 for	 an	 increase	 in	 isoflurane	




concentration	 was	 never	 needed	 in	 any	 of	 the	 experiments	 after	 transfer	 to	 the	
experimental	 box,	 indicating	more	 than	 adequate	 anaesthetic	 depth	 during	 the	 period	 of	
neuromuscular	block.	
2.3.9.	 	 Animal	Endpoint	












Figure	 13:	 Group	 assignment	 to	 experimental	 drug	 protocols	 (A)	 Magnesium	 dose-effect	
experiment	(B)	Magnesium	recurarisation	experiment	
2.4.1.	 	 Magnesium	dose-effect	experiment	
Rats	 were	 assigned	 to	 0,	 10,	 30	 or	 100	 mg/kg	 dose	 group	 (Figure	 13:	 A).	 After	 pre-
experimental	preparation	and	60	seconds	of	baseline	recording	had	been	completed,	0.1	mL	
per	 100	 g	 body	 weight	 of	 the	 test	 solution	 was	 injected	 into	 the	 intravenous	 cannula	
extension	tube.	Using	the	LabChart	software,	a	marker	was	placed	on	the	recording	and	the	




60 second baseline recording












































When	 recovery	 of	 fourth	 twitch	 of	 the	 Train-of-Four	 twitches	 had	 occurred,	 a	 comment	
marker	 was	 placed	 on	 the	 recording	 after	 which	 0.1	 mL	 per	 100	 g	 body	 weight	 of	 the	
assigned	 neuromuscular	 block	 reversal	 agent	 was	 injected	 into	 the	 intravenous	 cannula	
extension	 tube.	 The	 intravenous	 line	 was	 flushed	 with	 1.5	mL	 of	 saline	 over	 15	 seconds	




>	 0.85	 for	 longer	 than	 2	minutes,	 a	 comment	marker	was	 placed	 on	 the	 recording,	 after	
which	0.1	mL	per	100	g	body	weight	(30	mg/kg)	of	magnesium	sulphate	was	 injected	 into	




















Time	points	of	 drug	 administration	 and	 spontaneous	 recovery	of	 T1,	 T2,	 T3,	 and	T4	were	
also	determined	if	applicable.		
2.6.	 	 Data	analysis	




These	are	variables	 that,	 if	 significantly	different	between	 the	experimental	 groups,	 could	
potentially	contribute	towards	differences	observed	in	the	outcome	(hypothesis	answering)	
variables.	
The	weight	 of	 the	 rat	 (Wrat),	maintenance	 dose	 of	 isoflurane	 ([Iso]ave)	 administered	 after	
































To	 assess	 the	 recovery	 profile	 from	 the	 impairment	 produced	 by	 the	 different	 doses	 of	




The	weight	 of	 the	 rat	 (Wrat),	maintenance	 dose	 of	 isoflurane	 ([Iso]ave)	 administered	 after	
starting	mechanical	ventilation,	and	 the	baseline	heart	 rate	 (HRbase)	prior	 to	administering	
the	rocuronium	were	compared	between	experimental	groups.	
Time	 from	 induction	 of	 anaesthesia	 (Tanaesthesia)	 to	 administration	 of	 rocuronium	 was	




twitch.	 Comparison	of	 the	 raw	T1	 value	 at	 the	 time	of	magnesium	administration	 (T1base)	
between	experimental	groups	was	performed	to	assess	these	potential	variations.	
To	assess	whether	rats	in	different	experimental	groups	were	exposed	to	a	similar	degree	of	
neuromuscular	 block,	 the	 spontaneous	 recovery	 from	 NMB	 was	 assessed	 and	 compared	
between	the	experimental	groups.		
The	 time	 taken	 from	 the	 administration	 of	 rocuronium	 to	 the	 recovery	 of	 the	 four	 TOF	
twitches	(R-T1,	R-T2,	R-T3	and	R-T4)	to	detectable	levels	was	calculated.	























The	 degree	 of	 impairment	 of	 neuromuscular	 transmission	 produced	 by	 magnesium	
administration	 was	 as	 the	 lowest	 TOF-R	 (TOFmin)	 and	 %T1	 (%T1min)	 reached	 within	 200	
seconds	of	administering	the	magnesium.	
In	 order	 to	 account	 for	 variation	 in	 the	 actual	 TOF-R	 at	 the	 time	 of	 magnesium	
administration	 (especially	 in	 the	 SPON	 group),	 maximum	 decrease	 in	 TOF-R	 (𝛥TOF)	 and	






The	 peak	 onset	 time	 of	 recurarisation	 was	 calculated	 from	 the	 difference	 in	 time	 from	
magnesium	administration	to	the	time	of	TOFmin	(TOFonset)	and	%T1min	(%T1onset).	
2.6.1.3.4.	 Recovery	from	recurarisation	
In	 order	 to	 assess	 the	 degree	 to	 which	 neuromuscular	 transmission	 had	 recovered	 15	















an	 observational	 study,	 but	 agreement	 with	 the	 ethics	 committee	 that	 6	 rats	 per	 group	









In	 the	 event	 Shapiro	 Wilk	 test	 returned	 a	 p-value	 less	 than	 0.05,	 the	 data	 was	 log-






























ANOVA	 was	 used	 to	 assess	 if	 there	 were	 differences	 between	 the	 compared	 groups	
(p<0.05).	 If	 the	 Kruskall-Wallis	 ANOVA	 returned	 a	 p-value	 of	 less	 than	 0.05,	 a	 Bonferroni	




























0.2528	 (0.1376)	 for	60	mg/kg	group	and	0.4979	 (0.1551)	 for	100	mg/kg	group.	Significant	








The	 mean	 %T1min	 obtained	 after	 the	 test	 dose	 of	 magnesium	 being	 administered	 was	
90.73%	 (±1.544%)	 for	 0	 mg/kg	 group,	 94.36%	 (±1.352%)	 for	 10	 mg/kg	 group,	 93.69%	
(±2.082%)	 for	 30	 mg/kg	 group,	 75.52%	 (±18.078%)	 for	 60	 mg/kg	 group	 and	 41.45%	
(±18.128%)	 for	100	mg/kg	group.	 Significant	differences	were	only	observed	between	 the	






























































Figure	15:	Magnesium-induced	neuromuscular	 impairment	as	measured	by	%T1.	 (A)	 Time	




















































as	 these	 were	 the	 only	 groups	 to	 show	 impairment	 in	 neuromuscular	 transmission	
compared	to	the	0	mg/kg	(saline)	group.	
The	 mean	 time	 taken	 for	 TOF-R	 to	 reach	 it’s	 minimum	 (TOFmin)	 after	 the	 test	 dose	 of	
magnesium	was	 administered	was	 140.0	 seconds	 (±31.0	 seconds)	 in	 60	mg/kg	 group	 and	
248	 seconds	 (±33.5	 seconds)	 in	 100	 mg/kg	 group,	 with	 a	 significant	 difference	 between	
these	two	groups	(p=0.0004).	(Figure	16)	
The	 mean	 time	 taken	 for	 %T1	 to	 reach	 it’s	 minimum	 (%T1min)	 after	 the	 test	 dose	 of	
magnesium	was	 administered	was	 133.3	 seconds	 (±31.0	 seconds)	 in	 60	mg/kg	 group	 and	
264.0	 seconds	 (±21.9	 seconds)	 in	 100	mg/kg	 group,	with	 a	 significant	difference	between	
these	two	groups	(p<0.0001).	(Figure	16)	
	
Figure	 16:	 Time	 to	 onset	 of	 maximum	 impairment	 of	 neuromuscular	 transmission	 as	
measured	 by	%T1	 (orange)	 and	 TOF-R	 (green).	Mean	 ±	 SEM	 *	 significant	 difference	 from	





























The	 mean	 TOF900	 (TOF-R	 15	 minutes	 after	 magnesium	 administration)	 (Figure	 17:B)	 was	
found	to	be	0.924	(±0.0143)	in	the	0	mg/kg	group,	0.957	(±0.0268)	in	the	10	mg/kg	group,	
0.952	 (±0.0205)	 for	 30	 mg/kg	 group,	 0.913	 (±0.0492)	 for	 60	 mg/kg	 group	 and	 0.712	
(±0.1303)	for	100	mg/kg	group.	Significant	differences	were	observed	only	between	the	100	

















































The	 aim	 of	 the	 magnesium	 recurarisation	 experiment	 was	 to	 explore	 the	 interaction	 of	
residual	 NMBA	 at	 the	 NMJ	 and	 magnesium-induced	 depression	 of	 ACh	 release	 on	





18:	B)	was	 found	 to	be	493.3	 seconds	 (±77.63	 seconds)	 in	 the	NEO	group,	 223.3	 seconds	








Figure	18:	Rate	of	Neuromuscular	block	 reversal.	 (A)	 Time	course	of	TOF-R	 recovery	after	
reversal	agent	administration	(i.e.	T4	Recovery).	Mean	±	SEM	(B)	Time	from	reversal	agent	
administration	(time	of	T4	Recovery)	to	TOF-R	>	0.9	(i.e.	time	of	magnesium	administration).	






































































SPON	group,	0.731	 (±0.0712)	 for	 the	NEO	group,	0.616	 (±0.1399)	 for	 the	SUG4	group	and	




SPON	group,	0.174	 (±0.0717)	 for	 the	NEO	group,	0.280	 (±0.1164)	 for	 the	SUG4	group	and	





SPON	group,	94.6%	 (±3.25%)	 for	 the	NEO	group,	87.6%	 (±9.60%)	 for	 the	SUG4	group	and	











Figure	 19:	 Magnesium	 recurarisation	 compared	 between	 neuromuscular	 block	 reversal	
regimes,	 as	 measured	 by	 TOF-R.	 (A)	 Trace	 showing	 magnitude	 and	 time	 course	 of	
magnesium	recurarisation.	Mean	±	SEM.	 (B)	Maximal	depression	of	TOF-R	(𝛥TOF)	 induced	
by	magnesium	compared	by	neuromuscular	block	reversal	regime.	Mean	±	SEM.	*significant	














































Figure	 20:	 Magnesium	 recurarisation	 compared	 between	 neuromuscular	 block	 reversal	
regimes,	as	measured	by	%T1.	(A)	Trace	showing	magnitude	and	time	course	of	magnesium	
recurarisation.	Mean	±	SEM.	(B)	Maximal	depression	of	%T1	(𝛥%T1)	induced	by	magnesium	
















































The	 mean	 time	 taken	 for	 TOF-R	 to	 reach	 it’s	 minimum	 (TOFmin)	 after	 magnesium	
administration	was	120.0	seconds	(±17.89	seconds)	 in	SPON	group,	103.3	seconds	(±15.06	
seconds)	 in	NEO	group,	130.0	seconds	(±10.95	seconds)	 in	SUG4	group	and	111.4	seconds	
(±10.69	 seconds)	 in	 SUG16	group,	with	 significant	differences	only	observed	between	 the	
SUG4	group	and	NEO	group	(p=0.019).	(Figure	21)	
The	 mean	 time	 taken	 for	 %T1	 to	 reach	 it’s	 minimum	 (%T1min)	 after	 magnesium	





































The	mean	 TOF900	 (TOF-R	 15	minutes	 after	magnesium	 administration)	 (Figure	 22:	 B)	 was	
found	 to	be	0.804	 (±0.0991)	 in	 the	SPON	group,	0.895	 (±0.0171)	 in	 the	NEO	group,	0.725	




The	mean	 R25%	 (Time	 taken	 to	 recover	 25%	 of	 the	maximum	 recurarisation	 effect	 after	
time	of	TOF-Rmin)	(Figure	23)	was	found	to	be	133.3	seconds	(±53.16	seconds)	in	the	SPON	
group,	90.0	seconds	(±30.30	seconds)	in	the	NEO	group,	170.0	seconds	(±80.75	seconds)	for	
the	 SUG4	 group	 and	 65.7	 seconds	 (±27.60	 seconds)	 for	 the	 SUG16	 group.	 Significant	
differences	were	observed	between	the	SUG4	and	SUG16	groups	(p=0.011).	
The	mean	 R50%	 (Time	 taken	 to	 recover	 50%	 of	 the	maximum	 recurarisation	 effect	 after	
time	of	TOF-Rmin)	(Figure	23)	was	found	to	be	230.0	seconds	(±95.29	seconds)	in	the	SPON	
group,	153.3	seconds	 (±56.10	seconds)	 in	 the	NEO	group,	333.3	seconds	 (±94.52	seconds)	
for	 the	 SUG4	group	and	120.0	 seconds	 (±63.25	 seconds)	 for	 the	 SUG16	group.	 Significant	








after	 recurarisation	 illustrating	 the	 recovery	 of	 TOF-R.	Mean	 ±	 SEM	 (B)	 TOF-R	 value	 900	












































Figure	 23:	 Time	 course	 of	 TOF-R	 recovery	 from	 recurarisation	 using	 recovery	 to	 %	 of	



































anaesthesia)	 as	 well	 as	 to	 improve	 the	 stability	 of	 the	 procedure/technique	 to	 provide	
optimal	 experimental	 conditions	 –	 as	 identified	 from	 challenges	 encountered	 in	 previous	
use	of	 this	model.	A	 significant	 contribution	of	 this	work	 is	 refinement	of	 the	model.	 The	
exact	modifications	that	were	made	are	described	in	Appendix	A:	Supplementary	Methods.	
4.2.	 	 Magnesium	dose-effect	experiment	
This	 experiment	 sought	 to	 investigate	 the	 neuromuscular	 impairing	 effect	 of	 a	 range	 of	
intravenous	 magnesium	 sulphate	 doses	 in	 this	 in	 vivo	 rat	 model	 of	 neuromuscular	
transmission.	The	results	of	the	magnesium	dose-effect	experiment	and	it’s	implications	for	
the	 rest	 of	 the	 study,	 as	well	 as	 its	 potential	 applications	 towards	 clinical	 practice	will	 be	
discussed	in	this	section.	
In	this	experiment	it	was	shown	that	intravenous	magnesium	sulphate	was	able	to	produce	






was	significantly	 faster	 in	 the	 rats	given	60	mg/kg	compared	 to	 those	given	100	mg/kg	of	




between	 these	 two	 groups,	 this	may	 just	 reflect	 a	 greater	 time	 to	 reach	 a	 larger	 level	 of	
depression.	
Recovery	 from	 neuromuscular	 impairment	 15	minutes	 after	magnesium	was	 found	 to	 be	




competitive	 inhibition	 of	 calcium	 influx	 through	 P/Q-type	 VGCCs	 and	 thus	 reducing	 the	
quantal	release	of	ACh	[98-100].	This	may	be	explained	by	reduction	of	the	safety	factor	of	





prejunctional	effects	magnesium	produces.	A	 recent	 study	appears	 to	have	elaborated	on	
this	 by	 showing	 that	 magnesium	 decreases	 cation	 conductance	 at	 the	 postjunctional	
nAChRs,	 that	which	produces	 the	MEPP,	by	acting	as	a	non-competitive	antagonist	 to	 the	
receptor	[111].	The	IC50	of	magnesium	for	this	effect	(concentration	of	the	drug	necessary	to	
produce	 50%	 inhibition	 of	 the	 target	 function)	 is	 29.2mmol/L	 however,	 a	 concentration	
beyond	what	can	reasonably	be	assumed	to	have	been	reached	in	our	animal	model,	or	as	
the	authors	concede,	with	therapeutic	use	of	magnesium.	In	fact,	in	order	to	produce	a	20%	





absence	 of	 NMBAs	 was	 performed,	 before	 investigating	 how	 it	 interacts	 with	 them.	 In	





[87,	 89,	 91-94,	 157-159].	 A	 study	 investigating	 the	 neuromuscular	 response	 (using	 TOF-R	
and	T1)	to	a	range	of	magnesium	doses	has	as	of	yet,	not	been	published.	
It	 is	 important	 to	point	out	 that	while	no	neuromuscular	 impairment	was	observed	 in	 the	
magnesium	dose	groups	of	10	mg/kg	and	30	mg/kg,	this	does	not	imply	a	lack	of	decrease	in	
ACh	 released.	 The	 neuromuscular	 junction’s	 safety	 margin	 protects	 the	 efficiency	 of	 its	
transmission	by	releasing	far	greater	amounts	of	ACh	than	is	necessary	to	produce	an	action	
potential,	 even	 taking	 into	 consideration	 the	 substantial	 portion	 hydrolysed	 by	 AChE.	 In	
order	 to	 observe	 a	 prejunctionally	mediated	 decrease	 in	 TOF-R	 or	 T1	 (measures	 of	mild-




The	 major	 finding	 of	 this	 dose	 characterising	 study	 has	 clearly	 shown	 that	 30	 mg/kg	 of	
magnesium	 is	 not	 able	 to	 produce	 detectable	 neuromuscular	 impairment	 when	
administered	 alone,	 as	 measured	 by	 T1	 or	 TOF-R.	 It	 is	 suspected	 that	 any	 decrease	 in	
neuromuscular	 transmission	 in	 the	 recurarisation	 model	 after	 the	 administration	 of	 30	




of	 magnesium	 (given	 as	 a	 bolus)	 show	 no	 neuromuscular	 effect,	 indicate	 that	 (from	 a	
neuromuscular	point	of	view)	 it	might	be	possible	 to	safely	administer	 these	doses	 to	 the	
clinical	patient,	with	relatively	 little	concern	 for	neuromuscular	compromise.	While	 the	60	
mg/kg	dose	of	magnesium	produced	neuromuscular	 impairment,	 this	effect	was	mild	and	
transient,	especially	given	the	fact	that	it	was	given	as	a	bolus.	Since	magnesium	is	usually	
administered	 clinically	 as	 an	 infusion	 over	 several	 minutes,	 the	 effect	 seen	 with	 the	 60	
mg/kg	dose	may	be	even	smaller	if	given	in	this	manner.		
Although	 these	 data	 indicate	 a	 safe	 range	 of	magnesium	 doses	 for	 clinical	 use,	 it	 is	 very	






order	 to	 verify	 the	 results	 obtained	 in	 this	 study	 and	whether	 they	 can	be	 reproduced	 in	
humans.	
4.3.	 	 Magnesium	recurarisation	experiment	
This	 study	 sought	 to	 validate	 and	 further	 explore	 the	 results	 obtained	 in	 the	 previous	
honours	 studies	 conducted	 in	 this	 laboratory	 in	 2012	 [156]	 (See	 Section	 1.6.3.1.	 Previous	
recurarisation	data),	by	exploring	the	phenomenon	of	magnesium-induced	reinstatement	of	
NMB	 (magnesium	 recurarisation)	after	NMB	 reversal.	 The	aim	was	 to	 compare	 this	effect	
between	 the	choice	of	 reversal	 regime,	namely	 reversal	with:	neostigmine/glycopyrrolate,	
two	 different	 doses	 of	 sugammadex	 (4	 mg/kg	 and	 16	 mg/kg)	 and	 when	 reversal	 was	
omitted.	 This	 section	will	 discuss	 the	 results	 of	 the	magnesium	 recurarisation	experiment	
i.e.	 the	 differences	 between	 reversal	 regimes,	 the	 recurarisation	 effect	 itself,	 as	 well	 as	
recovery	 from	 recurarisation.	 The	 implications	 of	 these	 results	 on	 our	 understanding	 of	
neuromuscular	block	pharmacology	and	neuromuscular	physiology	will	also	be	discussed,	as	
well	as	how	this	may	apply	to	the	clinical	management	of	a	patient.	
From	 the	 results	 of	 the	magnesium	dose-effect	 experiment	 in	 this	 study	 (Results:	 Section	
3.1,	 Discussion:	 4.1)	 that	 showed	 30	 mg/kg	 of	 magnesium	 was	 not	 able	 to	 produce	
neuromuscular	block	 in	 the	 absence	of	NMBAs,	 it	was	 concluded	 that	 the	neuromuscular	
impairment	observed	in	the	previous	honours	study	[156]	after	administration	of	30	mg/kg	
of	magnesium	post-sugammadex	reversal	had	to	reflect	the	rebinding	of	the	rocuronium	to	
the	 postjunctional	 nAChR.	 It	 was	 hypothesised	 that	 with	 sugammadex	 reversal,	 only	
sufficient	 rocuronium	 is	 removed	 to	 liberate	 enough	 receptors	 to	 produce	 a	 TOF-R	 >	 0.9,	
leaving	behind	significant	 residual	 rocuronium	with	 the	potential	 to	 rebind	 the	 receptor	 if	
conditions	 were	 changed.	 To	 test	 this,	 higher	 doses	 of	 sugammadex	 (2-	 and	 8-	 fold	 the	









The	 magnitude	 of	 magnesium	 recurarisation	 was	 greatest	 in	 the	 rats	 that	 received	 no	
reversal	 agent	 and	 were	 allowed	 to	 recover	 spontaneously	 from	 NMB.	 The	 next	 largest	
recurarisation	effect	was	observed	in	rats	reversed	with	a	sugammadex	(4	mg/kg),	followed	
by	 reversal	 with	 neostigmine/	 glycopyrrolate,	 while	 the	 group	 of	 rats	 reversed	 with	
sugammadex	(16	mg/kg)	showed	the	smallest	effect.		
The	most	 likely	explanation	of	 these	 findings	probably	 relates	 to	 the	 safety	margin	of	 the	
neuromuscular	 junction	 and	 the	 pharmacology	 of	 neuromuscular	 blocking	 agents	 such	 as	











for	 the	 receptor	 would	 decrease,	 and	 the	 likelihood	 of	 a	 NMBA	 molecule	 binding	 the	
receptor	instead	of	ACh	would	increase,	thus	reinstating	neuromuscular	block.	
The	 second	 mechanism	 of	 magnesium’s	 neuromuscular	 impairing	 effect	 is	 through	
diminished	 conductance	 through	 the	 ion	 channel	 of	 the	 nAChR	 in	 response	 to	 ACh	
activation	 [111].	This	effect	was	unlikely	 to	be	 relevant	 to	 the	neuromuscular	 impairment	
observed	 in	the	magnesium	dose-effect	experiment	of	 this	study,	where	NMBAs	were	not	
present.	 However	 in	 the	 same	 study,	 in	 the	 presence	 of	 vecuronium,	 a	 non-depolarising	





blockade	 of	 ACh	 stimulation	 by	 as	 much	 as	 20%.	 Given	 the	 continued	 presence	 of	
rocuronium	 in	 the	 neuromuscular	 cleft	 at	 the	 time	 of	 magnesium	 administration	 in	 this	
study,	 and	 magnesium’s	 ability	 the	 enhance	 the	 antagonistic	 effect	 of	 NMBA	 at	 the	
postjunctional	 nAChR,	 magnesium’s	 postjunctional	 effects	 (and	 to	 what	 degree	 it	
contributes	towards	the	recurarisation	effect	observed)	is	worth	considering.		
4.3.1.1.	 Recurarisation	after	reversal	was	omitted	
A	 profound	magnesium	 recurarisation	 effect	 occurred	 after	 neuromuscular	 block	 reversal	
was	omitted,	and	rocuronium	neuromuscular	block	recovered	spontaneous	to	TOF-R	>	0.9.	








In	 this	 study,	 reversal	 of	 neuromuscular	 block	 with	 a	 combination	 of	 neostigmine/	
glycopyrrolate	 was	 also	 not	 able	 to	 prevent	 magnesium	 recurarisation,	 with	 significant	
impairment	in	neuromuscular	transmission,	that	returned	to	near	baseline	values	within	7	-	
8	 minutes.	 These	 results	 were	 expected,	 since	 similar	 findings	 were	 described	 in	 a	 case	
report	by	Fawcett	and	Stone	[90].	The	case	report	describes	a	patient	who	was	administered	
20	mg/kg	of	magnesium	 for	a	 rapid	atrial	 arrhythmia	after	 reversal	of	 cisatracurium	NMB	
with	2	standard	doses	of	neostigmine/	glycopyrrolate.	The	patient,	who	at	the	time	had	no	
neuromuscular	 monitoring,	 progressed	 to	 respiratory	 arrest	 and	 required	 tracheal	
intubation	and	assisted	ventilation	for	20	minutes	until	no	neuromuscular	impairment	was	







increased	 concentration	 of	 ACh	 overpowering	 the	 competitive	 binding	 affinity	 of	
rocuronium	for	the	nicotinic	cholinergic	receptor.	It	is	thus	not	surprising	that	magnesium’s	
ability	 to	 decrease	 ACh	 release	 is	 able	 to	 cause	 rebinding	 of	 residual	 rocuronium	 to	 the	
receptor,	 as	 the	 action	 of	 neostigmine	 is	 to	 maintain	 a	 increased	 concentrations	 of	 the	
transmitter,	but	does	not	affect	the	quantity	of	transmitter	released.	
4.3.1.3.	 Recurarisation	after	reversal	with	sugammadex	
The	 magnesium	 recurarisation	 result	 observed	 in	 the	 sugammadex	 4	 mg/kg	 group	 was	
significant	 both	 in	 its	magnitude	 and	 recovery	 profile	 from	 the	 recurarisation	 effect.	 It	 is	
noteworthy	however	that	when	NMB	was	reversed	was	a	higher	dose	of	sugammadex	(16	
mg/kg)	the	magnitude	of	recurarisation	was	significantly	reduced.	
Sugammadex	 reverses	 rocuronium	 NMB	 by	 binding	 it	 in	 the	 plasma	 and	 promoting	 its	
diffusion	out	of	the	NMJ	[63,	161].	It	has	been	shown	that	sugammadex	is	more	rapid	in	its	






speed	 at	which	neuromuscular	 block	was	 reversed	 [63,	 163,	 170];	 it	 is	 believed	 that	 very	
little	rocuronium	would	remain	in	the	neuromuscular	junction	after	reversal	that	could	then	
rebind	the	receptor.		
The	 results	 of	 this	 study,	 however,	 reveal	 a	 noteworthy	 limitation	 in	 the	 suggested	
mechanism	 of	 sugammadex	 reversal.	 Up	 to	 a	 dose	 of	 4	 mg/kg,	 sugammadex	 does	 bind	
enough	 rocuronium	 to	 cause	 sufficient	 movement	 thereof	 to	 the	 intravascular	






In	 perusing	 the	 clinical	 and	 pharmacological	 literature,	 this	 concept	 in	 the	mechanism	 of	
NMB	and	its	reversal	appears	be	understated.		
A	significant	residual	amount	of	rocuronium	still	appears	to	remain	 in	the	NMJ	(at	 least	 in	
this	 rodent	model),	which	has	 the	potential	 to	 rebind	 the	nicotinic	 receptor.	Additionally,	
due	to	sugammadex’s	lack	of	effect	on	AChE,	ACh	concentrations	remain	unenhanced,	and	
thus	 neuromuscular	 transmission	 is	 constantly	 dependent	 on	 the	 physiological	
concentration	of	ACh	outcompeting	the	residual	concentration	of	rocuronium	for	occupancy	
of	 the	 nicotinic	 receptor.	 Thus,	 any	 decrease	 in	 the	 release	 of	 ACh	 (such	 as	 caused	 by	
magnesium)	will	 diminish	 the	 safety	margin	of	neuromuscular	 transmission	 in	 such	a	way	
that	favours	the	binding	of	the	rocuronium	over	ACh	to	the	receptor,	thus	reinstating	NMB.	
4.3.2.	 	 Recovery	profile	from	recurarisation	
Further	 inspection	 of	 the	 data	 revealed	 that	 the	 recovery	 profile	 from	 magnesium	
recurarisation	after	 reversal	with	 sugammadex	 (4	mg/kg)	 showed	a	gradual	 recovery	over	
the	first	seven	minutes	after	magnesium	and	eventual	levelling	out	at	a	sub-baseline	value,	
while	a	similar	magnitude	of	recurarisation	after	neostigmine	reversal	showed	a	consistent	
return	 to	 baseline	 (TOF-R>0.9)	 at	 approximately	 6	 minutes	 post-magnesium,	 which	 was	





through	 inhibition	 is	 able	 to	 elevate	 these	 levels,	 and	 at	 least	 partially	 antagonise	 the	
neuromuscular	effects	of	magnesium	[171].	
It	 is	 noteworthy	 that	 when	 the	 sugammadex	 dose	 used	 for	 reversal	 was	 substantially	
increased	 (from	 4	 mg/kg	 to	 16	 mg/kg),	 in	 addition	 to	 the	 magnitude	 of	 the	 magnesium	
recurarisation	effect	being	reduced	and	the	recovery	profile	(in	terms	of	recovery	of	25	and	
50%	 of	 the	 recurarisation	 effect)	 also	 significantly	 improved.	 This	 reflects	 a	 greater	








(in	 increasing	 order)	 between	 NMB	 reversal	 agents	 (i.e.	 reversal	 rate)	 was:	 neostigmine/	
glycopyrrolate	<	sugammadex	(4	mg/kg)	<	sugammadex	(16	mg/kg).	Significant	differences	
were	 observed	 between	 neostigmine/	 glycopyrrolate	 and	 both	 sugammadex	 doses,	
however	no	significant	differences	were	observed	between	the	two	sugammadex	doses.		
It	is	worth	noting	that	the	occurrence	of	recurarisation	in	the	sugammadex	group	may	be	in	
part	 due	 to	 one	 of	 its	 properties	 that	make	 it	 so	 popular	 as	 a	 reversal	 agent,	 namely	 its	
faster	time	of	reversal.	The	time	taken	to	reverse	NMB	from	T4	recovery	to	a	TOF-R	>	0.9	
was	 much	 shorter	 with	 sugammadex	 reversal	 compared	 to	 neostigmine	 reversal,	 during	
which	 time	 less	 spontaneous	 elimination	 of	 rocuronium	 from	 the	 plasma	 and	 NMJ	 had	
occurred	 compared	 to	 neostigmine	 reversed	 rats.	 It	 could	 however	 be	 argued,	 that	 the	
sugammadex-induced	 diffusion	 of	 rocuronium	 from	 the	 NMJ	 to	 the	 intravascular	




were	 found	 to	 be	 significantly	 different,	 the	maximum	difference	 in	 between	 groups	was	
approximately	 one	 minute,	 bringing	 into	 question	 the	 clinical	 (and	 in	 this	 model,	
experimental)	 significance	 of	 the	 differences	 in	 onset	 of	 recurarisation,	 compared	 to	 the	
magnitude	of	the	effect.	
4.4.	 	 Limitations	of	the	study	







clinical	 scenario	 is	 not	 possible.	While	 in	 vivo	 animal	 studies	 can	 reveal	 much	 about	 the	
effects	and	 interactions	of	 various	drugs	on	physiology	or	pathology,	 the	 results	obtained	
should	be	used	to	infer	mechanisms	and	create	further	hypotheses.	Animal	studies	should	
certainly	 not	 be	 used	 to	 dictate	 (or	 change)	 clinical	 practice,	 however	 they	 form	 an	
important	 step	 towards	answering	a	clinical	hypothesis,	hence	 the	alternative	name	“pre-
clinical	studies”.	
4.4.2.	 	 Anaesthetic	agent	
One	 of	 the	 more	 obvious	 limitations	 in	 this	 study	 is	 the	 continual	 use	 of	 a	 volatile	 (i.e.	
isoflurane)	anaesthetic.	The	choice	of	anaesthetic	was	for	ethical	reasons,	as	it	provided	the	
best	stability	of	maintaining	anaesthetic	depth,	due	to	continuous	administration	through	a	




the	 volatile	 anaesthetic.	 However,	 due	 to	 ethical	 concerns	 related	 to	 animal	welfare	 and	
regulation	of	anaesthetic	depth	maintenance	–	the	use	of	volatile	anaesthesia	was	chosen.	
Isoflurane,	and	other	volatile	anaesthetics,	have	been	shown	to	exert	depressive	effects	on	
the	NMJ.	 It	 is	not	known,	 if,	or	to	what	degree,	these	effects	may	influence	the	validity	of	
this	study,	however	the	following	information	may	assist	in	rationalising	the	interpretation	
of	the	results.	
Karis	 et	 al.	 concluded	 from	 their	 work	 on	 in	 vitro	 frog	 nerve-muscle	 that	 the	 volatile	
anaesthetics	action	on	the	NMJ	is	postjunctionally	mediated	[172].	Kobayashi	et	al.	came	to	
a	 similar	 conclusion	 after	 in	 vitro	 investigations	 using	 rat	 phrenic	 nerve-hemidiaphragm	
preparations	[173].	There	have	been	studies	that	have	shown	volatile	anaesthetics	to	inhibit	
calcium	 currents	 through	 a	 variety	 of	 VGCCs	 [174,	 175]	 in	 the	 brain,	 including	 the	 P-type	






of	 ACh	 at	 the	 mouse	 NMJ,	 through	 inhibition	 of	 prejunctional	 voltage-gated	 sodium	
channels	[176].		
The	 ability	 of	 volatile	 anaesthetics	 to	 potentiate	 the	 neuromuscular	 impairment	 effect	 of	




The	 mechanism	 of	 the	 interaction	 of	 volatile	 anaesthetics	 with	 NMBA	 has	 also	 been	




study	was	attempting	 to	mimic,	namely	magnesium	administration	 in	 the	PACU	 (i.e.	 after	
anaesthesia	 had	 been	 terminated).	 However,	 one	 can	 infer	 the	 results	 of	 this	 study	 as	
mimicking	 the	 worst-case	 clinical	 scenario	 –	 for	 example,	 recurarisation	 occurring	 after	
magnesium	 was	 being	 administered	 to	 the	 patient	 just	 a	 few	 minutes	 after	 anaesthetic	
delivery	was	discontinued.	
Additionally,	 significant	 differences	 in	 the	 average	 isoflurane	 concentration	 ([Iso]ave)	were	
observed	 in	 the	magnesium	dose-effect	experiment	between	 the	saline	group	and	groups	
10,	30,	60	and	100	mg/kg	of	magnesium.	This	could	potentially	be	a	confounding	variable,	as	
the	 question	 of	 whether	 the	 lack	 of	 neuromuscular	 impairment	 observed	 in	 the	 saline	
control	 group	 is	 due	 to	 the	 lack	 of	 magnesium	 or	 the	 reduced	 isoflurane	 concentration.	
However,	given	that	the	rats	in	the	10	mg/kg	magnesium	dose	group	also	showed	no	signs	
of	 neuromuscular	 impairment,	 and	 the	 concentration	 of	 isoflurane	 did	 not	 differ	
significantly	with	those	in	the	groups	30	and	100	mg/kg	of	magnesium,	it	is	unlikely	that	this	








The	 study	 design	 did	 not	 incorporate	 blood	 sampling,	 for	 the	 following	 reasons.	 This	 is	 a	
technical	 limitation,	 as	 concern	 of	 compromising	 the	 rat	 was	 based	 on:	 repeated	 blood	





The	 lack	of	data	on	serum	magnesium	 levels	prior	 to	and	a	 few	minutes	after	magnesium	
administration	 in	 this	 study	 makes	 it	 difficult	 to	 correlate	 degree	 of	 neuromuscular	
impairment	 produced	 with	 the	 concentration	 of	 magnesium	 at	 the	 NMJ	 induced	 by	 the	
magnesium	bolus.		
It	should	however	be	noted	that	the	objective	of	these	experiments	was	to	determine	the	
neuromuscular	 impairing	 effect	 of	 a	 specified	 dose	 of	 magnesium,	 not	 to	 the	 plasma	
magnesium	 concentration	 reached.	 In	 clinical	 perioperative	 anaesthetic	 practice,	
magnesium	 is	 rarely	 titrated	 to	 serum	 levels,	 but	 rather	 infused	 or	 injected	 according	 to	
dose-response	relationships	already	established.	
4.4.3.2.		 Lack	of	blood	gas	analysis	
A	 further	 limitation	was	not	 taking	 into	account	possible	pH	effects	 in	 the	 face	of	 the	 rat	
being	 ventilated.	 The	 concern	 here	would	 be	 alkalosis,	 however	 great	 care	was	 taken	 to	
ventilate	the	rat	as	close	to	true	physiological	conditions	as	possible	(see	section	2.3.2.).	The	










pharmacology,	 utilise	 intravenous	 infusions	 of	 test	 drugs	 compared	 to	 the	 intravenous	
boluses	 used	 in	 this	 study.	 This	 was	 taken	 into	 account	 but	 not	 included	 in	 this	 study	
protocol.	While	effects	of	magnesium	and	other	drugs	tend	to	produce	larger	effects	when	
given	 as	 a	 fast	 bolus,	 compared	 to	 infusion,	 it	 is	 believed	 that	 the	 use	 of	 boluses	 may	
provide	a	situation,	as	discussed	above,	of	a	worst-case	clinical	scenario.	
4.5.		 	 Clinical	applications	
The	 results	 obtained	 in	 this	 study	 seem	 to	 suggest	 that	 prevention	 of	 magnesium	





report	 by	 Fawcett	 and	 Stone	 [90]	 however	 confirmation	 of	 this	 effect	 in	 a	 controlled	
experiment	certainly	adds	confidence	to	the	observed	clinical	phenomenon.	
The	 observation	 of	 recurarisation	 after	 reversal	 with	 sugammadex	 might	 initially	 seem	







that	 can	potentially	 influence	 the	 safety	 factor	of	 the	NMJ	are	not	 limited	 to	magnesium,	
but	also	to	aminoglycoside	antibiotics	and	many	other	drugs	[189].	





dose,	 and	 thus	 8-fold	 the	 price.	 This	makes	 prophylactic	 reversal	 of	 NMB	with	 high-dose	
sugammadex	unfeasible.	If	magnesium	recurarisation	does	occur	in	a	patient,	however,	the	
results	 of	 this	 study	 suggest	 that	 the	 administration	 of	 sugammadex	 in	 high	 doses	 (16	
mg/kg)	 could	 potentially	 extract	 sufficient	 rocuronium	 to	 accelerate	 recovery	 from	 the	
recurarisation	 effect,	 and	 rapidly	 restore	 neuromuscular	 transmission	 (rescue	 treatment).	
Additional	studies	are	needed	to	confirm	these	suggestions	however,	before	these	types	of	
recommendations	can	be	put	into	common	clinical	practice.	
The	 results	 of	 this	 study,	 from	 a	 clinical	 perspective,	 point	 out	 a	 possibly	 understated	
weakness	 in	 the	 reversal	 of	 NMB	 with	 sugammadex.	 The	 rate	 of	 neuromuscular	 block	
obtained	with	sugammadex	may	give	the	clinician	the	false	impression	of	complete	removal	
of	 NMBA	 in	 the	 NMJ.	 Residual	 NMB	 in	 the	 PACU,	 as	 discussed	 earlier	 (Section	 1.5.1.),	
continues	 to	persist	 (with	 great	 variability	 in	 reported	 incidences)	 in	hospitals	 around	 the	




With	 the	 results	 obtained	 in	 this	 animal	 study,	 new	 questions	 have	 arisen	 regarding	
magnesium’s	interaction	with	the	NMBAs	and	the	recurarisation	it	produces.		
Firstly,	given	that	magnesium	was	able	to	produce	recurarisation	in	rats	reversed	with	either	
sugammadex	 or	 neostigmine/glycopyrrolate,	 and	 that	 the	 mechanisms	 by	 which	 these	
agents	 reverse	 NMB	 are	 completely	 different,	 it	 is	 possible	 that	 the	 co-administration	 of	
these	 two	 agents	 for	 reversal	 of	 NMB	 might	 be	 able	 to	 protect	 against	 magnesium	
recurarisation.	 This	 is	 an	 especially	 intriguing	 question	 given	 that	 neostigmine’s	 recovery	
profile	from	recurarisation	shows	complete	recovery	to	baseline,	compared	to	the	recovery	
profile	observed	 in	 the	 sugammadex	group	showing	a	plateau	at	 suboptimal	 levels.	Could	
the	combined	use	of	both	neostigmine	and	sugammadex	allow	each	reversal	agent	to	make	









Secondly,	 it	 was	 observed	 that	 in	 this	 animal	 model,	 sugammadex	 was	 able	 to	 dose-
dependently	 reduce	 the	 magnesium	 recurarisation	 effect.	 However,	 routine	 reversal	 of	
NMB	 with	 high-doses	 of	 sugammadex	 on	 the	 basis	 of	 preventing	 recurarisation	 when	
magnesium	is	administered	is	most	likely	an	expensive	decision	to	make	in	clinical	practice,	
especially	 when	 magnesium	 administration	 is	 not	 anticipated.	 It	 is	 then	 possibly	 more	




sugammadex,	 what	 would	 the	 effect	 of	 subsequent	 neostigmine	 administration,	 or	 an	
additional	dose	of	sugammadex,	be	on	the	recurarisation	effect?		
Finally,	since	magnesium’s	mechanism	of	producing	recurarisation	is	hypothesised	to	occur	
due	 to	 competitive	 blockade	 of	 the	 prejunctional	 VGCC,	 what	 effect	 on	 already	 instated	
recurarisation	would	 occur	 by	 increasing	 the	 extracellular	 calcium	 concentration,	 thus	 re-
establishing	 prejunctional	 calcium	 currents?	 In	 other	 words,	 could	 the	 administration	 of	








carbamate),	 at	 concentrations	 needed	 to	 produce	 a	 surgical	 plane	 of	 anaesthesia	 (10	
mmol/kg	body	weight)	has	been	shown	in	vitro	to	produce	no	decrease	in	ACh	release	at	the	
NMJ	 [190].	 Additionally,	 urethane	 is	 an	 ideal	maintenance	 anaesthetic	 in	 terminal	 rodent	




hours).	 This	 is	 of	 particular	 use	 in	 NMB	 research	 where	 commonly	 used	 methods	 of	
monitoring	anaesthetic	depth	utilise	motor	reflexes	(such	as	the	toe	pinch-pedal	reflex),	are	
of	 little	 use	 given	 the	 blockade	 of	 neuromuscular	 transmission.	 Its	 main	 disadvantage	
however,	is	that	of	danger	to	the	persons	administering	the	agent	including	carcinogenicity,	
cytotoxicity	and	immunosuppression	[191].	These	can	be	minimised	however	with	training	
























relevant	 muscle	 weakness	 in	 patients	 with	 an	 otherwise	 normal	 safety	 margin	 of	
neuromuscular	 transmission	 i.e.	 absence	 of	 NMBA	 or	 neuromuscular	 pathology.	 Further	
clinical	 studies	 however	 are	 needed	 in	 order	 to	 verify	 these	 findings	 in	 humans	 before	
magnesium	 at	 these	 doses	 can	 be	 administered	 without	 concern	 of	 neuromuscular	
impairment.	
This	 study	 has	 also	 provided	 the	 basis	 for	 the	 use	 of	 a	 dose	 of	 30	 mg/kg	 magnesium	








rapid	 recovery	 to	 baseline	 conditions.	 However	 after	 reversal	 with	 a	 moderate	 dose	 of	
sugammadex,	poor	recovery	from	recurarisation	was	evident.		
A	dose-dependant	reduction	in	the	magnitude	and	improvement	of	the	recovery	profile	was	




clinically	 required	 for	 routine	 reversal	 to	 achieve	 this	 prophylactic	 effect	 makes	 it	
economically	unfeasible.		
The	results	of	this	study	are	the	first	of	its	kind,	in	that	it	is	the	first	controlled	study	(clinical	
or	 animal),	 to	 our	 knowledge,	 that	 has	 compared	 magnesium	 recurarisation	 between	








































































































































































































































































































































































































































































































































plate	 ensured	 that	 the	 tracheostomy	 always	 moved	 with	 the	 rat,	 vastly	 preventing	 the	








Modifications	 to	 the	 technique	 and	 equipment	 used	 for	 femoral	 vein	 cannulation	 was	
deemed	necessary	 in	order	to	reduce	the	time	spent	on	this	procedure,	thus	reducing	the	
time	 the	 rat	 was	 exposed	 to	 anaesthesia.	 Additionally,	 a	 need	 was	 determined,	 from	
previous	 experience	 with	 this	 model,	 for	 a	 method	 to	 secure	 the	 cannula	 firmly	 to	 the	
cannulation	site	to	prevent	dislodging	it	with	the	weight	of	the	extension	set	and	3-way	tap.		
A	 range	of	commercially	available	 intravenous	cannulas	were	 tested	 in	 rat	carcases	 (killed	
for	unrelated	reasons	to	this	project	and	with	permission	of	the	ethics	committee)	for	ease	
of	insertion	and	stability	after	securing	to	underlying	muscle.		















in	 this	model	with	 previous	 experiments.	 Contact	 between	 the	 two	 electrodes,	 especially	
once	the	experimental	recording	had	begun,	was	often	the	cause	of	sudden	changes	in	the	
quality	 of	 evoked-twitches	 that	 could	 not	 be	 attributed	 to	 experimental	 drug	
administration.	
In	 order	 to	 facilitate	 accurate	 and	 uninterrupted	 sciatic	 nerve	 stimulation,	 two	 partially	
insulated	silver	wire	electrodes	were	constructed	as	follows.	The	first	4	cm	of	an	8	cm	length	
of	 silver	wire	was	coiled	around	a	 small	wooden	stick	 to	create	a	 loop	 to	which	 the	hook	
connector	 clips	of	 the	output	 leads	of	 the	 stimulus	 isolation	unit	 could	easily	be	attached	
(Appendix	Figure	4:	A).	The	remaining	length	of	the	silver	wire	was	threaded	through	a	22G	
intravenous	 cannula	 to	 provide	 insulation	 and	 protection.	 This	 was	 especially	 important	
when	placed	 in	 situ	 next	 to	 the	 other	 electrode,	 and	 if	 contact	was	made	 could	 result	 in	
short	 circuiting	of	 the	 stimulation.	 The	 length	of	wire	 the	protruded	 from	 the	 cannula	 tip	
was	 bent	 into	 a	 hook	 shape	 to	 allow	 secure	 attachment	 to	 the	 sciatic	 nerve	 (Appendix	
Figure	4:	B).		












Appendix	 Figure	 5:	 GRASS	 Stimulator	 configured	 settings	 to	 obtain	 TOF-R	 stimulation	















threshold	 (Two-sided	 height):	 1mV,	 Peak	 Window:	 100ms,	 Baseline:	 average	 between	
peaks)	(Appendix	Figure	6:	B)	








Note:	 Due	 to	 nature	 of	 Peak	 Analysis	 software	 during	 recording,	 T4	 twitch	 was	 only	






























































































Appendix	 Table	 2:	 Rat	 data	 used	 for	 analysis	 compared	 to	 total	 rats	 used	 for	
experimentation	
D-2.	 	 Rat	weight	






Weight	(g):	 SD	(g):	 Range	(g):	 Significance:	
0	mg/kg	(Saline)	 367.50	 15.000	 350	-	380	 	
10	mg/kg	 353.75	 52.182	 285	-	410	 	
30	mg/kg	 323.00	 66.212	 270	-	450	 	
60	mg/kg	 298.33	 20.656	 275	-	325	 	
100	mg/kg	 303.00	 33.091	 260	-	350	 	
POOLED	 325.12	 47.661	 260	-	450	 -----------------	
Appendix	Table	3:	Descriptive	statistics	of	rat	weight	at	the	time	of	induction	of	anaesthesia	










Weight	(g):	 SD	(g):	 Range	(g):	 Significance:	
SPON	 332.50	 21.622	 300	-	355	 	
NEO	 339.17	 6.646	 330	-	350	 	
SUG4	 335.00	 25.298	 300	-	375	 	
SUG16	 322.14	 17.762	 290	-	340	 	
POOLED	 331.80	 19.033	 290	-	375	 -----------------	
Appendix	Table	4:	Descriptive	statistics	of	rat	weight	at	the	time	of	induction	of	anaesthesia	





The	 dose	 of	 isoflurane	 that	 was	 stabilised	 upon	 after	 tracheostomy	 and	 switch	 to	






[Iso]	(%):	 SD	(%):	 Range	(%):	 Significance:	
0	mg/kg	(Saline)	 1.68	 0.150	 1.6	-	1.9	 *	
10	mg/kg	 3.33	 0.330	 3	-	3.7	 	
30	mg/kg	 3.13	 0.383	 2.6	-	3.7	 	
60	mg/kg	 2.67	 0.121	 2.5	-	2.8	 #	
100	mg/kg	 3.22	 0.402	 2.8	-	3.7	 	
POOLED	 2.84	 0.634	 1.6	-	3.7	 ----------------------	
Appendix	 Table	 5:	 Descriptive	 statistics	 of	 average	 isoflurane	 concentration	 in	 the	
magnesium	 dose-effect	 experiment.	 	 One-way	 ANOVA	 revealed	 significant	 differences	
between	the	groups	 (p<0.0001).	*	 Indicates	significant	difference	to	10,	30,	100	 (p<0.001)	









[Iso]	(%):	 SD	(%):	 Range	(%):	 Significance:	
SPON	 2.33	 0.532	 1.4	-	2.8	 	
NEO	 2.65	 0.105	 2.5	-	2.8	 	
SUG4	 2.80	 0.283	 2.4	-	3.2	 	
SUG16	 2.70	 0.183	 2.4	-	2.9	 	
POOLED	 2.62	 0.342	 1.4	-	3.2	 -----------------	
Appendix	 Table	 6:	 Descriptive	 statistics	 of	 average	 isoflurane	 concentration	 in	 the	
magnesium	 dose-effect	 experiment.	 	 Kruskall-Wallis	 ANOVA	 revealed	 no	 significant	
differences	between	the	groups	(p=0.2408).		
D-4.	 	 Anaesthesia	time	(Induction	to	start	of	experimental	protocol)	
This	 is	 the	 time	 from	 the	 induction	 of	 anaesthesia	 to	 the	 administration	 of	 the	 first	 test	
drug.	This	measure	was	compared	between	groups	to	account	for	variability	in	the	duration	
of	 time	 spent	 under	 anaesthesia	 (and	 thus	 exposure	 to	 isoflurane)	 prior	 to	 starting	 the	
experimental	protocol.	
D-4.1.	 	 Magnesium	dose-effect	experiment	







0	mg/kg	(Saline)	 184.3	 10.34	 170	-	194	 	
10	mg/kg	 187.0	 19.17	 168	-	212	 	
30	mg/kg	 175.0	 30.43	 130	-	220	 	
60	mg/kg	 138.7	 6.53	 129	-	149	 	
100	mg/kg	 177.4	 35.32	 130	-	210	 	
POOLED	 170.2	 28.53	 129	-	220		 ----------------------	
Appendix	 Table	 7:	 Descriptive	 statistics	 of	 the	 time	 from	 induction	 of	 anaesthesia	 to	
administration	of	magnesium,	in	the	magnesium	dose-effect	experiment.		One-way	ANOVA	













SPON	 161.8	 21.64	 138	-	186	 *	
NEO	 141.2	 10.80	 127	-	157	 	
SUG4	 155.5	 19.23	 140	-	192	 	
SUG16	 134.0	 11.34	 121	-	157	 	
POOLED	 147.6	 19.02	 140	-	192	 -----------------	
Appendix	 Table	 8:	 Descriptive	 statistics	 of	 the	 time	 from	 induction	 of	 anaesthesia	 to	
administration	 of	 rocuronium,	 in	 the	 magnesium	 recurarisation	 experiment.	 	 One-way	




The	 Train-of-Four	 Ratio	 value	 at	 the	 time	 of	 administering	magnesium	was	 compared	 to	
account	for	variations	in	the	baseline	efficiency	of	neuromuscular	transmission.		
Due	 to	 the	 differences	 in	 state	 of	 neuromuscular	 physiology	 at	 the	 time	 of	 magnesium	








0	mg/kg	(Saline)	 0.9375	 0.01056	 0.9283	-	0.9476	 	
10	mg/kg	 0.9574	 0.02795	 0.9301	-	0.9956	 	
30	mg/kg	 0.9533	 0.02105	 0.9188	-	0.9757	 	
60	mg/kg	 0.9435	 0.00692	 0.9321	-	0.9539	 	
100	mg/kg	 0.9503	 0.00887	 0.9351	-	0.9580	 	
POOLED	 0.9485	 0.01651	 0.9188	-	0.9956	 ----------------------	
Appendix	 Table	 9:	 Descriptive	 statistics	 of	 the	 baseline	 TOF-R	 prior	 to	 administering	






The	 raw	 T1	 value	 at	 the	 time	 of	 administering	magnesium	was	 compared	 to	 account	 for	
variations	in	the	contraction	strength	of	the	muscle.		
Due	to	the	gradual	fade	 in	T1	height	over	time,	coupled	with	differences	 in	the	time	from	







0	mg/kg	(Saline)	 166.62	 12.738	 153.9	-	184.3	 	
10	mg/kg	 165.73	 16.860	 144.9	-	184.0	 	
30	mg/kg	 116.72	 39.446	 76.9	-	186.1	 	
60	mg/kg	 107.14	 18.398	 84.4	-	129.5	 	
100	mg/kg	 124.32	 48.058	 89.4	-	207.1	 	
POOLED	 131.76	 38.079	 76.9	-	207.1	 ----------------------	
Appendix	 Table	 10:	 Descriptive	 statistics	 of	 the	baseline	 raw	T1	 value,	 in	 the	magnesium	
dose-effect	 experiment.	 	 One-way	 ANOVA	 revealed	 significant	 differences	 (p=0.0211),	
however	Bonferroni	posthoc	test	showed	no	significant	differences	between	groups.	
D-6.	 	 Spontaneous	recovery	of	NMB	(Pre-reversal	parameters)	














SPON	 396.7	 67.43	 280	-	480	 	
NEO	 386.6	 97.70	 280	-	560	 	
SUG4	 553.3	 184.90	 260	-	720	 	
SUG16	 442.86	 96.21	 260	-	540	 	
POOLED	 444.80	 129.39	 260	-	720	 -----------------	
T2	Recovery	
SPON	 526.7	 73.39	 380	-	580	 	
NEO	 480.0	 75.89	 400	-	600	 	
SUG4	 693.3	 199.47	 420	-	900	 	
SUG16	 560.0	 117.19	 380	-	740	 	
POOLED	 564.8	 142.63	 380	-	900	 -----------------	
T3	Recovery	
SPON	 593.3	 80.66	 440	-	660	 	
NEO	 553.3	 97.71	 460	-	720	 	
SUG4	 786.7	 203.44	 540	-	1020	 	
SUG16	 631.4	 138.98	 440	-	860	 	
POOLED	 640.8	 156.89	 440	-	1020	 -----------------	
T4	Recovery	
SPON	 630.0	 89.22	 460	-	700	 	
NEO	 586.7	 104.05	 460	-	760	 	
SUG4	 840.0	 218.72	 600	-	1100	 	
SUG16	 660.0	 140.95	 480	-	900	 	
POOLED	 678.4	 167.82	 460	-	1100	 -----------------	
Appendix	Table	11:	Descriptive	statistics	of	the	time	to	recovery	of	T1,	T2,	T3	and	T4	of	the	
TOF	 twitches	 after	 rocuronium	 administration.	 One-way	 ANOVA	 of	 recovery	 of	 T1	
(p=0.0898),	 T2	 (p=0.0816)	and	T3	 (p=0.0609)	 revealed	no	 significant	differences.	One-way	



















SPON	 0.224	 0.0430	 0.178	-	0.292	 	
NEO	 0.247	 0.0318	 0.198	-	0.278	 	
SUG4	 0.205	 0.0460	 0.153	-	0.282	 	
SUG16	 0.230	 0.0494	 0.174	-	0.321	 	
POOLED	 0.226	 0.0433	 0.153	-	0.321	 -----------------	


















      weight       25    0.93889      1.698     1.082    0.13954
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
  more  
      weight           5         303    33.09078        260        350
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                    
      weight           6    298.3333    20.65591        275        325
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                    
      weight           6         323    66.21178        270        450
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                    
      weight           4      353.75    52.18157        285        410
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                    
      weight           4       367.5          15        350        380
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max









Bartlett's test for equal variances:  chi2(4) =   9.4330  Prob>chi2 = 0.051
    Total             54518.64     24      2271.61
                                                                        
 Within groups      37277.0833     20   1863.85417
Between groups      17241.5567      4   4310.38917      2.31     0.0930
                                                                        
    Source              SS         df      MS            F     Prob > F














         iso       25    0.94884      1.422     0.719    0.23602
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
         iso           5        3.22    .4024923        2.8        3.7
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
         iso           6    2.666667     .121106        2.5        2.8
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                  
         iso           6    3.133333    .3829709        2.6        3.7
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                  
         iso           4       3.325    .3304038          3        3.7
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                  
         iso           4       1.675         .15        1.6        1.9
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 0
Bartlett's test for equal variances:  chi2(4) =   7.6001  Prob>chi2 = 0.107
    Total           9.63760043     24   .401566685
                                                                        
 Within groups       1.8496671     20   .092483355
Between groups      7.78793334      4   1.94698333     21.05     0.0000
                                                                        
    Source              SS         df      MS            F     Prob > F













                0.000      1.000      1.000      0.070
     100        1.545      -.105    .086667    .553333
          
                0.001      0.032      0.151
      60      .991667   -.658333   -.466667
          
                0.000      1.000
      30      1.45833   -.191667
          
                0.000
      10         1.65
                                                      
Col Mean            0         10         30         60
Row Mean- 
                                (Bonferroni)


























   a_time_mg       25    0.93908      1.693     1.076    0.14099
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
   a_time_mg           5       177.4    35.32421        130        210
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
   a_time_mg           6    138.6667    6.531973        129        149
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                  
   a_time_mg           6         175    30.43025        130        220
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                  
   a_time_mg           4         187    19.16594        168        212
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                  
   a_time_mg           4      184.25    10.34005        170        194
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 0
Bartlett's test for equal variances:  chi2(4) =  12.2000  Prob>chi2 = 0.016
    Total             19539.36     24       814.14
                                                                        
 Within groups      11257.2833     20   562.864167
Between groups      8282.07667      4   2070.51917      3.68     0.0211
                                                                        
    Source              SS         df      MS            F     Prob > F








                1.000      1.000      1.000      0.139
     100        -6.85       -9.6        2.4    38.7333
          
                0.075      0.050      0.153
      60     -45.5833   -48.3333   -36.3333
          
                1.000      1.000
      30        -9.25        -12
          
                1.000
      10         2.75
                                                      
Col Mean            0         10         30         60
Row Mean- 
                                (Bonferroni)















      t1base       25    0.94161      1.622     0.989    0.16126
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
      t1base           5      124.32    48.05765       89.4      207.1
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
      t1base           6    107.1353    18.39814       84.4      129.5
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                  
      t1base           6    116.7165     39.4457      76.86      186.1
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                  
      t1base           4     165.725    16.86048      144.9        184
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                  
      t1base           4     166.625    12.73876      153.9      184.3
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 0
                         Comparison of t1base by dose
Bartlett's test for equal variances:  chi2(4) =   8.2641  Prob>chi2 = 0.082
    Total           34799.6888     24   1449.98703
                                                                        
 Within groups      20050.0771     20   1002.50386
Between groups      14749.6117      4   3687.40293      3.68     0.0211
                                                                        
    Source              SS         df      MS            F     Prob > F







                0.602      0.654      1.000      1.000
     100      -42.305    -41.405     7.6035    17.1847
          
                0.086      0.095      1.000
      60     -59.4897   -58.5897   -9.58117
          
                0.240      0.264
      30     -49.9085   -49.0085
          
                1.000
      10     -.900002
                                                      
Col Mean            0         10         30         60
Row Mean- 
                                (Bonferroni)















     tofbase       25    0.94696      1.474     0.793    0.21395
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
     tofbase           5      .95028      .00887      .9351       .958
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
     tofbase           6    .9435167     .006924      .9321      .9539
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                  
     tofbase           6      .95325    .0210471      .9188      .9757
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                  
     tofbase           4      .95735    .0279538      .9301      .9956
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                  
     tofbase           4     .937575    .0105629      .9283      .9476
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 0
                        Comparison of tofbase by dose
Bartlett's test for equal variances:  chi2(4) =   9.7147  Prob>chi2 = 0.046
    Total           .006539193     24   .000272466
                                                                        
 Within groups      .005448288     20   .000272414
Between groups      .001090905      4   .000272726      1.00     0.4301
                                                                        
    Source              SS         df      MS            F     Prob > F














      tofmin       25    0.79352      5.737     3.571    0.00018
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
   tofminlog       25    0.73657      7.320     4.069    0.00002
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
      tofmin           5      .45232    .1507308      .2793      .5844
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
      tofmin           6    .6957167    .1413277      .4718      .8736
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                  
      tofmin           6    .9349833    .0188816      .9022      .9589
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                  
      tofmin           4      .94315    .0263451      .9204      .9806
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                  
      tofmin           4        .925     .003587      .9207      .9293
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max










SAL		 VS.	 60mg	(p=0.018)	 	
100mg	(p<0.001)	
10mg		 vs.	 60mg	(p=0.009)	 	
100mg	(p<0.001)	




probability =     0.0006
chi-squared with ties =    19.675 with 4 d.f.
probability =     0.0006
chi-squared =    19.675 with 4 d.f.
                           
     100     5      18.00  
      60     6      48.00  
      30     6     118.00  
      10     4      79.00  
       0     4      62.00  
                           
    dose   Obs   Rank Sum  
                           
Kruskal-Wallis equality-of-populations rank test
                0.000      0.000      0.000      0.006
     100      -.47268    -.49083   -.482663   -.243397
          
                0.018      0.009      0.004
      60     -.229283   -.247433   -.239267
          
                1.000      1.000
      30      .009983   -.008167
          
                1.000
      10       .01815
                                                      
Col Mean            0         10         30         60
Row Mean- 
                                (Bonferroni)






















        dtof       25    0.76862      6.429     3.804    0.00007
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. 
     dtoflog       25    0.91007      2.499     1.872    0.03060
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
        dtof           5      .49794    .1550861       .352      .6735
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
        dtof           6       .2528    .1375892      .0992      .4723
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                  
        dtof           6    .0174667    .0155065      .0018      .0457
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                  
        dtof           4       .0142    .0031591      .0097      .0171
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                  
        dtof           4     .012575    .0076678      .0045      .0199
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max










SAL	 vs.		 60mg	(p=0.011)	 	
100mg	(p<0.001)	
10mg	 vs.	 60mg	(p=0.012)	 	
100mg	(p<0.001)	




probability =     0.0009
chi-squared with ties =    18.777 with 4 d.f.
probability =     0.0009
chi-squared =    18.770 with 4 d.f.
                           
     100     5     112.00  
      60     6     108.00  
      30     6      46.00  
      10     4      31.00  
       0     4      28.00  
                           
    dose   Obs   Rank Sum  
                           
Kruskal-Wallis equality-of-populations rank test
                0.000      0.000      0.000      0.005
     100      .485365     .48374    .480473     .24514
          
                0.011      0.012      0.005
      60      .240225      .2386    .235333
          
                1.000      1.000
      30      .004892    .003267
          
                1.000
      10      .001625
                                                      
Col Mean            0         10         30         60
Row Mean- 
                                (Bonferroni)





















       t1min       24    0.74882      6.775     3.901    0.00005
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. 
    t1minlog       24    0.67311      8.817     4.438    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
       t1min           5      41.452    18.12796      20.57      61.33
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
       t1min           6    75.51667    18.07794      41.22      91.45
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                  
       t1min           6    93.69333    2.082263       90.9      96.63
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                  
       t1min           4       94.36    1.351614      93.16      96.27
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                  
       t1min           3    90.72666    1.543708      88.95      91.74
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max















probability =     0.0009
chi-squared with ties =    18.819 with 4 d.f.
probability =     0.0009
chi-squared =    18.819 with 4 d.f.
                           
     100     5      18.00  
      60     6      50.00  
      30     6     113.00  
      10     4      78.00  
       0     3      41.00  
                           
    dose   Obs   Rank Sum  
                           
Kruskal-Wallis equality-of-populations rank test
. 
                0.000      0.000      0.000      0.002
     100     -49.2747    -52.908   -52.2413   -34.0647
          
                1.000      0.309      0.211
      60       -15.21   -18.8433   -18.1767
          
                1.000      1.000
      30      2.96667   -.666666
          
                1.000
      10      3.63333
                                                      
Col Mean            0         10         30         60
Row Mean- 
                                (Bonferroni)
























      dt1min       24    0.74338      6.922     3.945    0.00004
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
   dt1minlog       24    0.89580      2.811     2.107    0.01755
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
      dt1min           5      58.022    18.14471      38.38      78.59
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
      dt1min           6    24.02167    17.86151       8.54      58.07
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                  
      dt1min           6    5.703333    1.550712       3.38       7.91
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                  
      dt1min           4      5.3375    1.381506       3.52       6.85
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                  
      dt1min           3        8.48    1.726007       7.39      10.47
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max















probability =     0.0006
chi-squared with ties =    19.491 with 4 d.f.
probability =     0.0006
chi-squared =    19.491 with 4 d.f.
                           
     100     5     107.00  
      60     6     101.00  
      30     6      36.00  
      10     4      21.00  
       0     3      35.00  
                           
    dose   Obs   Rank Sum  
                           
Kruskal-Wallis equality-of-populations rank test
                0.000      0.000      0.000      0.002
     100       49.542    52.6845    52.3187    34.0003
          
                0.931      0.311      0.195
      60      15.5417    18.6842    18.3183
          
                1.000      1.000
      30     -2.77667    .365833
          
                1.000
      10      -3.1425
                                                      
Col Mean            0         10         30         60
Row Mean- 
                                (Bonferroni)

























     t1onset       11    0.89951      1.627     0.907    0.18230
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
     t1onset           5         248     33.4664        220        300
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
     t1onset           6         140    30.98387        120        200
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
 Pr(T < t) = 0.0002         Pr(|T| > |t|) = 0.0004          Pr(T > t) = 0.9998
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0
Ho: diff = 0                                     degrees of freedom =        9
    diff = mean(60) - mean(100)                                   t =  -5.5544
                                                                              
    diff                  -108    19.44413               -151.9857   -64.01433
                                                                              
combined        11    189.0909    19.32754    64.10219    146.0265    232.1553
                                                                              
     100         5         248    14.96663     33.4664     206.446     289.554
      60         6         140    12.64911    30.98387    107.4844    172.5156
                                                                              
   Group       Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval]
                                                                              































    tofonset       11    0.90173      1.591     0.863    0.19405
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
    tofonset           5         264     21.9089        240        300
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
    tofonset           6    133.3333    30.11091        100        180
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
. 
 Pr(T < t) = 0.0000         Pr(|T| > |t|) = 0.0000          Pr(T > t) = 1.0000
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0
Ho: diff = 0                                     degrees of freedom =        9
    diff = mean(60) - mean(100)                                   t =  -8.0586
                                                                              
    diff             -130.6667    16.21461               -167.3467   -93.98667
                                                                              
combined        11    192.7273    21.95412    72.81359    143.8104    241.6441
                                                                              
     100         5         264    9.797959     21.9089    236.7965    291.2035
      60         6    133.3333    12.29273    30.11091    101.7339    164.9328
                                                                              
   Group       Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval]
                                                                              





























      tof900       25    0.71705      7.862     4.215    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. 
   tof900log       25    0.66018      9.443     4.590    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
      tof900           5      .71218    .1302933      .5267       .848
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 100
                                                                                                                  
      tof900           6    .9132333    .0491862      .8194      .9663
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 60
                                                                                                                  
      tof900           6       .9515    .0204581      .9217      .9797
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 30
                                                                                                                  
      tof900           4     .957075     .026805      .9395       .997
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> dose = 10
                                                                                                                  
      tof900           4       .9236    .0142927      .9085      .9415
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max














probability =     0.0031
chi-squared with ties =    15.913 with 4 d.f.
probability =     0.0031
chi-squared =    15.907 with 4 d.f.
                           
     100     5      16.00  
      60     6      72.50  
      30     6     112.50  
      10     4      78.00  
       0     4      46.00  
                           
    dose   Obs   Rank Sum  
                           
Kruskal-Wallis equality-of-populations rank test
                0.001      0.000      0.000      0.001
     100      -.21142   -.244895    -.23932   -.201053
          
                1.000      1.000      1.000
      60     -.010367   -.043842   -.038267
          
                1.000      1.000
      30        .0279   -.005575
          
                1.000
      10      .033475
                                                      
Col Mean            0         10         30         60
Row Mean- 
                                (Bonferroni)


























      weight       25    0.97811      0.608    -1.016    0.84516
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
      weight           6         335    25.29822        300        375
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S4
                                                                                                                    
      weight           7    322.1429    17.76165        290        340
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S16
                                                                                                                    
      weight           6       332.5    21.62175        300        355
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S
                                                                                                                    
      weight           6    339.1667    6.645801        330        350
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = N
                      Comparison of weight by treatment
Bartlett's test for equal variances:  chi2(3) =   6.8074  Prob>chi2 = 0.078
    Total                 8694     24       362.25
                                                                        
 Within groups      7651.19048     21   364.342404
Between groups      1042.80952      3   347.603175      0.95     0.4326
                                                                        
    Source              SS         df      MS            F     Prob > F

















         iso       25    0.85401      4.057     2.863    0.00210
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. 
      isolog       25    0.74528      7.078     4.001    0.00003
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
         iso           6         2.8    .2828427        2.4        3.2
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S4
                                                                                                                    
         iso           7         2.7    .1825742        2.4        2.9
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S16
                                                                                                                    
         iso           6    2.333333     .531664        1.4        2.8
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S
                                                                                                                    
         iso           6        2.65    .1048809        2.5        2.8
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = N
. 
probability =     0.2408
chi-squared with ties =     4.199 with 3 d.f.
probability =     0.2576
chi-squared =     4.036 with 3 d.f.
                               
          S4     6     100.00  
         S16     7     102.50  
           S     6      52.50  
           N     6      70.00  
                               
    treatm~t   Obs   Rank Sum  
                               














      tanaes       25    0.89857      2.818     2.118    0.01708
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk tanaes
. 
   tanaeslog       25    0.92865      1.983     1.399    0.08089
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
      tanaes           6       155.5    19.23278        140        192
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S4
                                                                                                                    
      tanaes           7         134    11.34313        121        157
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S16
                                                                                                                    
      tanaes           6    161.8333    21.63716        138        186
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S
                                                                                                                    
      tanaes           6    141.1667     10.7966        127        157
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max












Bartlett's test for equal variances:  chi2(3) =   2.1722  Prob>chi2 = 0.537
    Total           .068588858     24   .002857869
                                                                        
 Within groups       .04277019     21   .002036676
Between groups      .025818668      3   .008606223      4.23     0.0174
                                                                        
    Source              SS         df      MS            F     Prob > F
                        Analysis of Variance
                0.810      1.000      0.119
      S4      .040497   -.016628    .063339
          
                1.000      0.027
     S16     -.022842   -.079967
          
                0.239
       S      .057125
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)






























       toft4       25    0.97879      0.589    -1.080    0.86002
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
       toft4           6    .2045667    .0459591       .153      .2822
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S4
                                                                                                                    
       toft4           7    .2298429    .0494143      .1743      .3207
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S16
                                                                                                                    
       toft4           6      .22375    .0429543      .1775      .2916
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S
                                                                                                                    
       toft4           6    .2467333    .0318149       .198      .2777
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = N
Bartlett's test for equal variances:  chi2(3) =   0.9706  Prob>chi2 = 0.808
    Total           .044964032     24   .001873501
                                                                        
 Within groups      .039498117     21   .001880863
Between groups      .005465915      3   .001821972      0.97     0.4260
                                                                        
    Source              SS         df      MS            F     Prob > F














          t1       25    0.93188      1.893     1.304    0.09604
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
          t1           6    553.3333    184.8964        260        720
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S4
                                                                                                                    
          t1           7    442.8571    96.21405        260        540
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S16
                                                                                                                    
          t1           6    396.6667    67.42897        280        480
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S
                                                                                                                    
          t1           6    386.6667    97.70705        280        560
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = N
Bartlett's test for equal variances:  chi2(3) =   5.3384  Prob>chi2 = 0.149
    Total               401824     24   16742.6667
                                                                        
 Within groups      296942.857     21   14140.1361
Between groups      104881.143      3    34960.381      2.47     0.0898
                                                                        
    Source              SS         df      MS            F     Prob > F

















          t2       25    0.89731      2.853     2.143    0.01604
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
       t2log       25    0.94303      1.583     0.939    0.17389
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
          t2           6    693.3333     199.466        420        900
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S4
                                                                                                                    
          t2           7         560    117.1893        380        740
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S16
                                                                                                                    
          t2           6    526.6667    73.39391        380        580
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S
                                                                                                                    
          t2           6         480    75.89466        400        600
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = N
Bartlett's test for equal variances:  chi2(3) =   3.0685  Prob>chi2 = 0.381
    Total            .26015889     24   .010839954
                                                                        
 Within groups      .190315812     21   .009062658
Between groups      .069843079      3   .023281026      2.57     0.0816
                                                                        
    Source              SS         df      MS            F     Prob > F


















          t3       25    0.90454      2.653     1.994    0.02306
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
       t3log       25    0.95023      1.383     0.663    0.25376
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
          t3           6    786.6667    203.4371        540       1020
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S4
                                                                                                                    
          t3           7    631.4286    138.9758        440        860
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S16
                                                                                                                    
          t3           6    593.3333    80.66391        440        660
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S
                                                                                                                    
          t3           6    553.3333    97.70705        460        720
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = N
                       Comparison of t3log by Treatment
Bartlett's test for equal variances:  chi2(3) =   1.8860  Prob>chi2 = 0.596
    Total            .24226477     24   .010094365
                                                                        
 Within groups      .171875525     21   .008184549
Between groups      .070389245      3   .023463082      2.87     0.0609
                                                                        
    Source              SS         df      MS            F     Prob > F


















          t4       25    0.89766      2.844     2.136    0.01632
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
       t4log       25    0.95060      1.373     0.647    0.25868
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. 
          t4           6         840    218.7236        600       1100
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S4
                                                                                                                    
          t4           7         660    140.9492        480        900
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S16
                                                                                                                    
          t4           6         630    89.21883        460        700
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = S
                                                                                                                    
          t4           6    586.6667    104.0513        460        760
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> treatment = N
Bartlett's test for equal variances:  chi2(3) =   1.5428  Prob>chi2 = 0.672
    Total           .243372272     24   .010140511
                                                                        
 Within groups      .169116893     21   .008053185
Between groups      .074255379      3   .024751793      3.07     0.0499
                                                                        
    Source              SS         df      MS            F     Prob > F






                0.055      0.212      0.342
      S4      .148793     .11651     .10058
          
                1.000      1.000
     S16      .048212    .015929
          
                1.000
       S      .032283
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)

































        t4mg       19    0.82481      3.999     2.784    0.00268
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
     t4mglog       19    0.88058      2.726     2.015    0.02198
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
        t4mg           6    223.3333    42.73952        180        280
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
        t4mg           7    154.2857    19.02379        140        180
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
        t4mg           6    493.3333    77.63161        380        600
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = N
probability =     0.0004
chi-squared with ties =    15.501 with 2 d.f.
probability =     0.0005
chi-squared =    15.229 with 2 d.f.
                               
          S4     6      61.00  
         S16     7      30.00  
           N     6      99.00  
                               
    reversal   Obs   Rank Sum  
                               






N	 	 VS.	 S4	(P<0.001)	 	
S16	(P<0.001)	
                0.000      0.080
      S4         -270    69.0476
          
                0.000
     S16     -339.048
                                
Col Mean            N        S16
Row Mean- 
                                (Bonferroni)





























t1min_adjust       24    0.76391      6.368     3.775    0.00008
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. 
t1min_adju~g       24    0.68338      8.541     4.373    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
t1min_adjust           6    87.55477    9.598487   75.20564   96.06595
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
t1min_adjust           7    94.71121    5.499392    84.0421        100
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
t1min_adjust           6    63.82567    21.79965   33.78397    94.1704
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S
                                                                                                                    
t1min_adjust           5    94.59788     3.24681   89.26627       97.4
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max










Spon.		 VS.	 N	(P=0.003)	 	
S4	(P=0.020)	
S16	(P=0.001)	
probability =     0.0095
chi-squared with ties =    11.451 with 3 d.f.
probability =     0.0095
chi-squared =    11.451 with 3 d.f.
                               
          S4     6      66.00  
         S16     7     121.00  
           S     6      31.00  
           N     5      82.00  
                               
    reversal   Obs   Rank Sum  
                               
Kruskal-Wallis equality-of-populations rank test
                1.000      0.020      1.000
      S4     -7.04311    23.7291   -7.15645
          
                1.000      0.001
     S16      .113332    30.8855
          
                0.003
       S     -30.7722
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)



























      dt1min       24    0.76391      6.368     3.775    0.00008
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. oneway dt1minlog reversal, bonferroni
   dt1minlog       24    0.97492      0.677    -0.797    0.78720
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
      dt1min           6    12.44524    9.598487    3.93405   24.79436
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
      dt1min           7    5.288786    5.499392          0    15.9579
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
      dt1min           6    36.17433    21.79965   5.829597   66.21603
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S
                                                                                                                    
      dt1min           5    5.402118    3.246808        2.6   10.73372
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max














Bartlett's test for equal variances:  chi2(3) =   1.8224  Prob>chi2 = 0.610
    Total           5.92520594     23   .257617649
                                                                        
 Within groups      2.86541628     20   .143270814
Between groups      3.05978966      3   1.01992989      7.12     0.0019
                                                                        
    Source              SS         df      MS            F     Prob > F
                        Analysis of Variance
. histogram dt1min, frequency
                1.000      0.265      0.276
      S4      .308774   -.469538    .447984
          
                1.000      0.002
     S16     -.139209   -.917522
          
                0.017
       S      .778313
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)
























     t1onset       23    0.96255      0.980    -0.042    0.51670
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
     t1onset           6    143.3333     29.4392        120        180
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
     t1onset           6         160    25.29822        140        200
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
     t1onset           6    103.3333    15.05545         80        120
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S
                                                                                                                    
     t1onset           5         116    26.07681         80        140
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = N
Bartlett's test for equal variances:  chi2(3) =   2.0054  Prob>chi2 = 0.571
    Total           23060.8696     22   1048.22134
                                                                        
 Within groups      11386.6667     19   599.298246
Between groups      11674.2029      3   3891.40097      6.49     0.0033
                                                                        
    Source              SS         df      MS            F     Prob > F






S16	 	 VS.	 N	(P=0.047)	 	 	
S	(P=0.005)	
	
. histogram t1onset, frequency
                0.485      0.064      1.000
      S4      27.3333         40   -16.6667
          
                0.047      0.005
     S16           44    56.6667
          
                1.000
       S     -12.6667
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)



























      tofmin       25    0.93494      1.808     1.211    0.11304
                                                                
    Variable      Obs       W           V         z       Prob>z
      tofmin           6    .6158333    .1399349       .439       .791
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
      tofmin           7    .8214286    .0938205        .67       .919
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
      tofmin           6    .4176667    .1641154       .229       .703
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S
                                                                                                                    
      tofmin           6    .7311667    .0711911       .649       .815
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = N
Bartlett's test for equal variances:  chi2(3) =   3.7761  Prob>chi2 = 0.287
    Total           .886542292     24   .036939262
                                                                        
 Within groups      .310732727     21   .014796797
Between groups      .575809564      3   .191936521     12.97     0.0001
                                                                        
    Source              SS         df      MS            F     Prob > F






S	 VS.	 N	(P=0.001)	 	
S16	(P<0.001)	
S4	 VS.	 S16	(P=0.038)	
                0.693      0.061      0.038
      S4     -.115333    .198167   -.205595
          
                1.000      0.000
     S16      .090262    .403762
          
                0.001
       S       -.3135
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)























        dtof       25    0.92446      2.099     1.516    0.06479
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
        dtof           6    .2801167    .1164236      .1376      .4321
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
        dtof           7    .0958571    .0847894      .0103      .2366
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
        dtof           6      .45075    .1412242      .1996      .5591
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S
                                                                                                                    
        dtof           6    .1743167     .071663      .0847      .2599
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = N
Bartlett's test for equal variances:  chi2(3) =   2.6095  Prob>chi2 = 0.456
    Total           .683365395     24   .028473558
                                                                        
 Within groups      .236306981     21   .011252713
Between groups      .447058415      3   .149019472     13.24     0.0000
                                                                        
    Source              SS         df      MS            F     Prob > F






S	 	 VS.	 N	(P=0.001)	 	 	
S16	(P<0.001)	
S4	 	 VS.	 S16	(P=0.031)	
	
                0.593      0.066      0.031
      S4        .1058   -.170633     .18426
          
                1.000      0.000
     S16      -.07846   -.354893
          
                0.001
       S      .276433
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)




















      tof900       25    0.88206      3.277     2.427    0.00762
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
   tof900log       25    0.85674      3.981     2.824    0.00237
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
      tof900           6    .7248333     .098834       .579       .822
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
      tof900           7    .8815714    .0738825       .733       .946
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
      tof900           6    .8043333    .0991073       .661       .913
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S
                                                                                                                    
      tof900           6    .8948333    .0171163       .877        .92
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max










S4	 VS.	 N	(P=0.008)	 	 	
S16	(P=0.011)	
probability =     0.0118
chi-squared with ties =    10.984 with 3 d.f.
probability =     0.0118
chi-squared =    10.984 with 3 d.f.
                               
          S4     6      35.00  
         S16     7     118.00  
           S     6      64.00  
           N     6     108.00  
                               
    reversal   Obs   Rank Sum  
                               
Kruskal-Wallis equality-of-populations rank test
                0.008      0.584      0.011
      S4         -.17     -.0795   -.156738
          
                1.000      0.568
     S16     -.013262    .077238
          
                0.369
       S       -.0905
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)























    tofonset       25    0.97614      0.663    -0.840    0.79957
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
    tofonset           6         130    10.95445        120        140
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
    tofonset           7    111.4286    10.69045        100        120
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
    tofonset           6         120    17.88854        100        140
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S
                                                                                                                    
    tofonset           6    103.3333    15.05545         80        120
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = N
Bartlett's test for equal variances:  chi2(3) =   1.8624  Prob>chi2 = 0.601
    Total                 6400     24   266.666667
                                                                        
 Within groups      4019.04762     21    191.38322
Between groups      2380.95238      3   793.650794      4.15     0.0187
                                                                        
    Source              SS         df      MS            F     Prob > F






S4	 VS.	 N	(P=0.019)	 	 	
                0.019      1.000      0.150
      S4      26.6667         10    18.5714
          
                1.000      1.000
     S16      8.09524   -8.57143
          
                0.296
       S      16.6667
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)





























         r25       25    0.90733      2.575     1.934    0.02658
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk r25
      r25log       25    0.96700      0.917    -0.178    0.57044
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk r25log
         r25           6         170    80.74652        100        320
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
         r25           7    65.71429    27.60262         20        100
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
         r25           6    133.3333    53.16641         40        200
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S
                                                                                                                    
         r25           6          90     30.3315         40        120
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = N
Bartlett's test for equal variances:  chi2(3) =   0.8986  Prob>chi2 = 0.826
    Total           1.64239507     24   .068433128
                                                                        
 Within groups      .977689572     21   .046556646
Between groups      .664705496      3   .221568499      4.76     0.0110
                                                                        
    Source              SS         df      MS            F     Prob > F






S4	 VS.	 S16	(P=0.011)	 	
                0.257      1.000      0.011
      S4      .268502    .116495    .426196
          
                1.000      0.105
     S16     -.157694   -.309701
          
                1.000
       S      .152007
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)
























. oneway r50 reversal, bonferroni
         r50       21    0.97098      0.711    -0.689    0.75467
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
         r50           3    333.3333    94.51631        260        440
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S4
                                                                                                                    
         r50           6         120    63.24555         20        200
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S16
                                                                                                                    
         r50           6         230    95.28903         80        340
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = S
                                                                                                                    
         r50           6    153.3333    56.09516         80        220
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
-> reversal = N
Bartlett's test for equal variances:  chi2(3) =   1.6844  Prob>chi2 = 0.640
    Total           207657.143     20   10382.8571
                                                                        
 Within groups           99000     17   5823.52941
Between groups      108657.143      3   36219.0476      6.22     0.0048
                                                                        
    Source              SS         df      MS            F     Prob > F


















                0.023      0.435      0.006
      S4          180    103.333    213.333
          
                1.000      0.139
     S16     -33.3333       -110
          
                0.599
       S      76.6667
                                           
Col Mean            N          S        S16
Row Mean- 
                                (Bonferroni)
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